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1 Summary 
Microorganisms communicate with each other through the secretion of molecules that 
accumulate in the environment and mediate specific responses upon reaching a specific 
threshold. This process has been termed quorum sensing and is essential to coordinate 
changes in behavior dependent on cell population density. Farnesol (FOH) is the first 
quorum sensing molecule described in a eukaryotic organism, and it is produced by the 
opportunistic pathogenic fungus Candida albicans. FOH regulates morphogenesis in C. 
albicans; however, we and others have described a new role of FOH as a compound with 
immunomodulatory properties. In particular, FOH showed to impair DC differentiation from 
monocytes, resulting in altered expression of surface markers and secretion of cytokines, 
thereby suppressing DC ability to induce T cell proliferation. However, the molecular 
mechanisms by which FOH modulates DC differentiation and maturation are poorly 
understood. The results of this study revealed that FOH regulates DC function through 
several signaling pathways. FOH modulates the expression of costimulatory molecules 
partially through activation of the nuclear receptors PPARγ, RARα and LXRα. In particular, 
FOH increased the expression of the lipid antigen-presenting molecule CD1d through 
activation of p38 MAPK and PPARγ/RARα signaling pathway. However, CD1d upregulation 
did not confer these cells an elevated capacity to activate invariant Natural Killer T (iNKT) 
cells. FOH-differentiated DC showed diminished secretion of IL-12 and increased IL-10 
release. Interestingly, reconstitution of the IL-12/IL-10 cytokine milieu restored FOH-
differentiated DC to activate iNKT, Th1 and regulatory T cells. Mechanistically, FOH 
modulates IL-10 and pro-inflammatory cytokines through activation of RARα, LXRα, MAPK 
and NF-κB signaling pathways. Altogether, our results showed that FOH induces paralysis 
of DC function through activation of nuclear receptors, MAPK and NF-κB signaling 
pathways. Since these cells play an important role in regulating the immune response during 
infection, this work supports the role of FOH as a virulence factor produced by C. albicans 
to overcome immune surveillance by DC.  
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2 Zussammenfassung 
Mikroorganismen kommunizieren miteinander durch die Sekretion von Molekülen, die sich 
in der Umwelt ansammeln und bei Erreichen eines bestimmten Schwellwertes bestimmte 
Reaktionen vermitteln. Dieser Prozess wird als Quorum Sensing bezeichnet und dient dazu, 
Verhaltensänderungen in Abhängigkeit der Zellpopulationsdichte zu koordinieren. Farnesol 
(FOH) ist das erste Quorum-Sensing-Molekül, das in einem eukaryotischen Organismus 
beschrieben wurde. Es wird von dem opportunistischen und pathogenen Pilz Candida 
albicans produziert und dient der Regulation der Morphogenese. Wir und andere haben eine 
neue Funktion von FOH beschrieben, in der es als Verbindung mit immunmodulatorischen 
Eigenschaften dient. FOH beeinträchtigte die Differenzierung von Monozyten zu 
Dendritischen Zellen (DZ), was zu einer veränderten Expression von Oberflächenmarkern 
und zur Sekretion von Zytokinen führte, wodurch die Fähigkeit der DZ zur Induktion der T-
Zell-Proliferation unterdrückt wurde. Die molekularen Mechanismen, über die FOH die 
Differenzierung und Reifung von DZ moduliert sind jedoch kaum bekannt. Die Ergebnisse 
dieser Studie zeigten, dass FOH die Funktion von DZ über mehrere Signalwege reguliert. 
FOH moduliert die Expression kostimulatorischer Moleküle teilweise durch Aktivierung der 
Nuklearrezeptoren PPARγ, RARα und LXRα. FOH erhöhte insbesondere die Expression 
des Lipidantigen-präsentierenden Moleküls CD1d durch Aktivierung des p38-MAPK- und 
PPARγ/RARα-Signalweges. Die Hochregulation von CD1d verlieh diesen Zellen jedoch 
keine erhöhte Fähigkeit, invariante natürliche Killer T (iNKT)- Zellen zu aktivieren. FOH-
differenzierte DZ zeigten eine verminderte IL-12 und eine erhöhte IL-10 Sekretion. 
Interessanterweise befähigte die Rekonstitution des IL-12/IL-10-Zytokinmilieus die FOH-
differenzierten DZ wieder, iNKT-, Th1- und regulatorische T-Zellen zu aktivieren. 
Mechanistisch modulierte FOH die Freisetzung von IL-10 und entzündungsfördernden 
Zytokinen durch Aktivierung von RARα-, LXRα-, MAPK- und NF-κB-Signalwegen. 
Insgesamt zeigten unsere Ergebnisse, dass FOH die Paralyse der DZ durch Aktivierung der 
Nuklearrezeptoren und über MAPK- und NF-κB -Signalwege induzierte. Da diese Zellen 
eine wichtige Rolle bei der Regulierung der Immunantwort bei Infektionen spielen, 
unterstützt diese Arbeit die Rolle von FOH als Virulenzfaktor, der von C. albicans produziert 
wird, um die Immunüberwachung durch DZ zu überwinden. 
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3 Introduction 
3.1 Candida albicans 
C. albicans is one of the most prominent fungal commensal and pathogen of humans. C. 
albicans colonizes the gastrointestinal tract, mouth, skin and the female reproductive tract 
(1, 2). To colonize these niches, the fungus is able to adapt to several environmental 
conditions, including oxygen levels, host microbiome or changes in pH (1). However, C. 
albicans can become pathogenic if the host develops specific risk factors, such as microbial 
dysbiosis, immunodeficiency, major surgery, the presence of venous catheter and antibiotics 
(2, 3). Indeed, C. albicans can cause a broad range of infections in human, including 
superficial infections, such as oral or vaginal candidiasis, and life-threatening systemic 
infections (1). C. albicans relies on several virulence factors, including the expression of 
adhesins and biofilm formation, secretion of cytolytic proteins and morphological plasticity 
(4-10). C. albicans is a polymorphic fungus that can grow as budding yeast, pseudophyphae 
and true-hyphae (1, 2). The yeast form is associated with colonization and dissemination, 
while the filamentous form is involved in adhesion, penetration and tissue invasion (5, 6). 
Different environmental conditions are known to influence morphological transition in C. 
albicans, such as pH, starvation, the presence of serum or N-acetylglucosamine, 
temperature and CO2 levels (6). Moreover, morphogenesis is also modulated by quorum 
sensing (QS), a mechanism of microbial communication to coordinate population density-
dependent changes in behavior. In QS, secreted molecules from growing microorganisms 
accumulate in the local environment and modulate specific responses once a critical 
threshold or concentration has been reached. The main QS molecules produced by C. 
albicans include tyrosol, farnesoic acid and farnesol (1, 11-13). Tyrosol decreases the lag 
phase growth and stimulates filamentation as well as biofilm formation. However, its effects 
are only observed in absence of farnesol (11, 14). Farnesoic acid and farnesol inhibits the 
switch from yeast to hyphae form in a growing population. However, the effect of farnesoic 
acid is less than farnesol and only produced by one strain of C. albicans (12).  
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3.2 Farnesol production by Candida albicans 
Farnesol (FOH) is a QS molecule produced mostly by C. albicans and inhibits the yeast to 
hyphae transition, which is one of the most important virulence factor associated with this 
fungus (1, 15). FOH is produced by C. albicans as a side product of the sterol biosynthetic 
pathway, which is essential for the membrane integrity of the fungus (16). Indeed, FOH is 
an acyclic sesquiterpene (isoprenoid/ 1-hydroxy-3, 7, 11-trimethyl-2, 6, 10-dodacatrien) 
produced by dephosphorylation of farnesol pyrophosphate (FPP), a key intermediate of the 
mevalonate pathway (17). Inhibition of the sterol synthetic pathway downstream of FOH 
induces accumulation of FPP, resulting in elevated concentration of FOH compared to 
untreated cells (18). Furthermore, inhibition of 3-hydroxy-methyl-glutaryl-CoA reductase 
(HMGR), necessary for mevalonate synthesis, reduces FOH production in C. albicans (19). 
Of the four existing isomers, only E-E FOH showed QS activity (20). Interestingly, FOH 
production is not unique to C. albicans. A study testing the capability of eight Candida 
species to produce FOH showed that C. dubliniensis can produce this QS molecule, but in 
much less quantities compared to C. albicans (21).  
Production of FOH by C. albicans is likely dependent on the coordinated activation of several 
genes. Particularly, DPP3 gene is known to be important for FOH biosynthesis in C. 
albicans. Production of FOH is significantly reduced in a DPP3 deletion mutant (22). 
Furthermore, overexpression of DPP3 increases the morphogenic-inhibitory effects of FOH 
(23). Furthermore, synthesis was enhanced in deletion mutants of the morphogenic 
repressor genes NRG1 and TUP1, as well as in the associated hyphal-maintenance gene 
EED1 (24-26).  
 Effects of farnesol on Candida albicans 
The most prominent effect of FOH is its ability to influence C. albicans morphology, by 
blocking the transition from yeast to filamentous cell without altering the growth rate (27, 28). 
Additionally, FOH inhibits biofilm formation in C. albicans. Ramage et al. showed that the 
effect of FOH on biofilm formation depends on the concentration of the compound and the 
initial time of adherence (29). While low FOH concentration did not affect biofilm formation, 
incubation with 300 µM FOH reduced C. albicans adherence and increased dispersal during 
the first 30 min of treatment. Interestingly, biofilm formation was impaired when cells were 
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incubated with 100 µM FOH for 24 hours (30). These results indicate that FOH treatment 
might promote C. albicans dispersal to colonize new niches. In addition to morphogenesis 
and biofilm formation, FOH regulates the expression of genes involved in drug resistance, 
iron transport, cell wall maintenance, oxidative stress, heat shock, surface hydrophobicity 
and iron transport (30-32).   
Several reports have shown that FOH impacts multiple signaling pathways in C. albicans. 
The Ras1-cAMP-PKA cascade is one of the first signaling pathways identified to be 
influenced by farnesol. Ras proteins are GTPases localized in the plasma membrane which 
plays an important role in filamentation (33). Piispanen et al. (34) showed that FOH cleave 
Ras1 from the plasma membrane and the resulting soluble Ras1 reduced the ability to 
activate the catalytic activity of the adenylyl cyclase Cyr1p, supporting the formation of yeast 
cells. One important event on Ras1 localization in the plasma membrane involves 
farnesylation of the protein, which facilitates Cyr1p binding to Ras1 (35, 36). Thus, FOH 
could also block Ras1 activity via inhibition of farnesylation (37). Interestingly, FOH alters 
several other signaling pathways, such as activation of the general stress mitogen-activated 
protein kinase (MAPK) Hog1 and the two components signaling via the Cek1-MAPK 
pathway and stabilization of transcription factors like Tup1/Nrg1, leading to repression of 
filamentation (15, 25, 38-40). Finally, FOH modulates the activation of Efg1 and Czf1 
transcription factors activities resulting in the transition from white to opaque cells, with 
opaque cells being killed at lower FOH concentrations (15, 41).  
 Farnesol effects on other microorganisms 
FOH does not only affect C. albicans itself but alters other microorganisms and cell types 
(15). FOH blocks conidation and germination of Aspergillus niger, Penicillium expansum, 
and Fusarium graminearum via deregulation of G-protein/cAMP signaling pathway and 
induction of apoptosis. Interestingly, the induction of cell death by FOH in Fusarium 
graminearum, Saccharomyces cerevisiae, A. nidulans and A. flavus is a process dependent 
on metacaspase activation and ROS production (42-47). However, a different study found 
that FOH alters the membrane integrity of microorganisms due to its amphiphilic 
characteristic (48). Indeed, FOH treatment showed to blocks actin cytoskeleton formation in 
A. fumigatus by misplacing the hyphal tip localization of two prenylated Rho family GTPases, 
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AfRho1 and AfRho2, while inhibiting the cell wall integrity signaling pathway (48). Similarly, 
FOH increases drugs susceptibility of Escherichia coli, and Staphylococcus aureus via 
disruption of the cell membrane, resulting in the reduce formation of biofilms (49, 50).  
 Farnesol effects on mammalian cells 
Besides FOH effects on C. albicans and other microorganisms, FOH has been shown to 
interact with mammalian cells. In particular, FOH induces apoptosis in several types of 
cancer cell lines, such as lung carcinoma cells, human oral squamous carcinoma cells, 
prostate cancer cells and breast cancer cells highlighting its relevance as a possible 
antineoplastic drug (51-54). However, some studies have found that FOH treatment also 
impacts viability of non-malignant cells. Particularly, FOH induces apoptosis and necrosis in 
spermatozoa (55). While FOH treatment reduced murine macrophages viability in vitro, the 
pro-apoptotic effect of this molecule on immune cells only occur at high concentrations (56, 
57). 
Although FOH inhibits filamentation in C. albicans, existing data suggest that FOH is likely 
a virulence factor promoting disease progression in systemic infections (22, 58). Treatment 
of C. albicans with subinhibitory concentrations of FOH-inducing azoles enhances virulence 
in a systemic candidiasis murine model (58). Furthermore, administration of FOH in mice 
infected with C. albicans reduced IL-12 and IFN-γ concentration, while increased kidney 
fungal burden and mortality (22). In accordance, infection with C. albicans strains that do 
not produce FOH showed reduced mortality in mice (22, 58). Likewise, treatment of mice 
with pravastatin, a HMG-CoA reductase inhibitor, decreased FOH production and enhanced 
viability during C. albicans infection (59). Interestingly, FOH treatment showed to be 
protective against oral candidiasis in mice.  
Further evidences support immunomodulatory properties of FOH. Specifically, FOH 
treatment stimulates the chemokinesis of murine macrophages in vitro and in vivo, and these 
effects were enhanced in the presence of yeast cell wall components and aromatic alcohols 
(60). Interestingly, FOH administration with zymosan resulted in modulation of RAW264.7 
macrophages genes expression, by enhancing IL-6, Toll-like receptor 2 (TLR2) and dectin-
1 expression (61). However, Leonhardt et al. showed that FOH alters neutrophils, 
monocytes and dendritic cells functionality (56). FOH treatment promotes activation of 
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neutrophils and monocytes. However, this did not correlate with elevated phagocytic activity. 
In contrast, FOH dramatically impaired the differentiation of monocytes into dendritic cells. 
Particularly, FOH modified the expression of costimulatory and antigen-presenting 
molecules. These changes in surface molecules were accompanied by enhanced anti-
inflammatory IL-10 and diminished IL-12 release and correlated with reduced capacity to 
induce T cell proliferation (56). Due to the increasing evidences of FOH as an important 
virulence factor and the relevance of dendritic cells in the anti-Candida immunity, this thesis 
focused in elucidating the molecular mechanisms in which FOH treatment orchestrates 
dendritic cells functionality.  
3.3 Role of dendritic cells in anti-Candida immune responses 
The innate immune system is the first-line of defense against invading pathogens, including 
C. albicans. While neutrophils and monocytes present one of the most important cellular 
components in the defense against this fungus, subsequent recognition and activation by 
dendritic cells leads to specific T cell anti-Candida immunity, which is important for fungal 
clearance (62, 63).  
 Dendritic cells 
The orchestration of an effective immune response depends on dendritic cells (DC), a class 
of cells derived from bone-marrow that can be found in virtually most peripheral tissues, 
blood and lymphoid organs (64). DC are able to process extra- and intracellular antigens 
and present these via Major Histocompatibility Complex (MHC) molecules to T cells (65). 
Thus, DC are the bridge between the innate and adaptive immunity. DC population 
comprised of different types of cells, each with specific functions. They can be classified in 
plasmocytoid DC, myeloid conventional DC 1 (cDC1), myeloid conventional DC 2 (cDC2), 
Langerhans cells and monocyte-derived DC (64). Plasmocytoid DC are mainly present in 
blood and are specialized to sense and respond to viral infection by a rapid secretion of type 
I and type III interferons (66). Myeloid cDC1 are present in blood and tissues. These cells 
have the capacity to present antigens via MHC class I to promote CD8+ T cells and NK cells 
activation through IL-12 production (64, 67). Myeloid cDC2 are present in blood, tissues and 
lymphoid organs. These cells are equipped with a range of C-type lectins, Toll-like receptors 
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(TLR), Nucleotide-binding oligomerization domain (NOD)-like receptors and Retinoic acid-
inducible gene-I (RIG)-like receptors that allow them to recognize several different types of 
Pathogen-associated molecular patterns (PAMP). In contrast to cDC1, these cells have the 
capacity to produce high amounts of IL-12, allowing them to activate Th1, Th17 and CD8+ T 
cells (64). Langerhans cells are skin-resident cells, specialized in production of pro-
inflammatory cytokines while also presenting antigens to CD8+ T cells (64).  
Several reports have shown that monocytes can migrate into tissues in response to local 
inflammation, rapidly acquiring key properties of DC such as expression of specific DC 
markers, present exogenous antigens to T cells and produce high amounts of inflammatory 
as well as anti-inflammatory cytokines (64). Monocytes differentiate into immature DC (iDC) 
specialized to engulf foreign antigens, resulting in antigens loaded into MHC molecules. 
Generation of mature DC (mDC) is achieved after activation of iDC with different antigens, 
mainly LPS, TNF-α or CD40L, leading to elevated expression of costimulatory molecules, 
migration to lymph nodes, antigen presentation to T cells and production of T cell-polarizing 
cytokines (68-70). Upon LPS recognition by TLR4, downstream adaptors are recruited into 
the intracellular domain of the receptor (Figure 1), such as the myeloid differentiation primary 
response gene 88 (MyD88), TIR domain-containing adaptor protein (TIRAP), TIR domain-
containing adaptor inducing IFN-β (TRIF) and TRIF-related adaptor protein (TRAM). 
Different TLR use different combination of adaptor proteins to determine downstream 
signaling. TLR 1, 2, 5 and 6 mainly use the MyD88-dependent pathway, while TLR4 use 
both downstream signaling pathway. MyD88 activation leads to recruitment and activation 
of the IRAK and TRAF6 kinases, which activate IκB kinase (IKK) and mitogen-activated 
protein kinase (MAPK) downstream signaling. IKK further phosphorylates iκB which leads 
to its degradation and subsequent nuclear translocation of the NF-κB transcription factor 
resulting in DC maturation by increasing the expression of costimulatory molecules and 
cytokines production (71-77). Activation of MAPK results in induction of the activator protein-
1 (AP-1) transcription factor, which has also a role in the transcription of pro-inflammatory 
cytokines (71-73). Notably, MAPK regulates DC maturation through phosphorylation of NF-
κB. Accordingly, inhibition of p38 and JNK MAPK activation blocked the upregulation of the 
costimulatory molecules and the release of pro-inflammatory cytokines induced by LPS 
stimulation, resulting in a reduced capacity to prime T cells (74, 78, 79). In contrast, the 
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MyD88-independent pathway leads to activation of a different transcription factor interferon 
response factor (IRF), which is mainly involved in the type-1 interferon production (71-73).  
 
Figure 1. TLR signaling pathway 
Maturation of DC is typically achieved through stimulation with TLR agonists. Upon recognition of 
TLR ligands, signaling is driven in a MyD88-dependent or independent manner. MyD88 activation 
leads to recruitment of IRAK and TRAF6, followed by activation of MAPK and IKK. IKK 
phosphorylates iκB, leading to degradation of iκB and nuclear translocation of NF-κB. The p38, JNK 
and ERK MAPK activate AP-1 and NF-κB transcription factors. The MyD88-independent pathway is 
mediated through the TRIF/TRAM adaptor protein complex, which enhances IRF nuclear 
translocation. Finally, AP-1, NF-κB and IRF mediate the transcription of genes involved in 
costimulatory molecules expression and cytokine production. Figure modified after (71-73) 
 
Due to the relevance of monocytes-derived DC in vivo, the development of protocols for in 
vitro generation of these cells has been used successfully to study DC biology. CD14+ 
monocytes can be isolated from donors and cultured in presence of GM-CSF and IL-4 for 6 
days to obtain iDC. iDC generated by this method resemble the surface molecule expression 
and morphology observed in vivo. iDC are characterized by enhanced capacity to bind and 
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process antigens while expressing markers including group 1 CD1 (CD1a, CD1b and CD1c). 
Moreover, mDC retain expression of CD1 molecules and upregulate antigen-presenting and 
costimulatory molecules on their surface, including MHC class I and II, CD40, CD80, CD86 
(64, 80-82).   
 DC antigen presentation and T cell polarization 
DC have the capacity to efficiently present antigens to T cells. This process is in part 
dependent on the optimal expression of antigen-presenting molecules, including as MHC 
class I and II molecules. While MHC class I present peptide antigens to CD8+ cytotoxic T 
cells, MHC class II activates CD4+ T helper cells (67). MHC class II proteins include HLA-
DR, HLA-DQ and HLA-DP, and are expressed on iDC and become highly up-regulated after 
iDC maturation. Efficient antigen presentation by DC correlates with the levels of these 
molecules on the surface (67, 83). Unlike MHC class I and II molecules which present 
peptides as antigens, members of the CD1 family present self- and foreign lipid antigens to 
T lymphocyte subsets. CD1 molecules are classified depended on their sequence homology 
into group 1 (CD1a-c), group 2 (CD1d) and group 3 (CD1e) (84, 85). While group 1 and 2 
are expressed on the surface, group 3 is located intracellularly and might play a role in 
antigen-processing rather than presentation (84-86). Group 1 family members present lipid 
antigens to conventional T cells, while CD1d functions as antigen-presenting molecule to a 
specific T cell subset known as invariant Natural Killer T cells (iNKT) (87, 88).  
In concert with signals triggered by peptide-MHC or lipid-CD1 complexes presentation, T 
cell activation requires a “second signal” triggered by costimulatory molecule interactions, 
mainly mediated by the expression of CD40, CD80 and CD86 on DC (89-91). Binding of 
CD80 and CD86 to their partner CD28 on T cells confers optimal production of IL-2, an 
important cytokine that promotes expansion and survival of T cells (90-92). However, the 
CD40/CD40L pathway also regulates T cell priming and differentiation. CD40 ligation on DC 
further increases the expression of costimulatory, adhesion and MHC molecules (89, 93). 
Consequently, DC produce an array of cytokines that direct CD4+T cell differentiation into 
one of the different subsets of effector T cells, such as T helper 1 (Th1), Th2, Th17 or 
regulatory T cells (Treg) (94). Th1, Th2 and Th17 subsets are defined based on the different 
cytokine combinations that they secrete. Th1 cells development is induced when IL-12 is 
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present, and play an important role in activating monocytes, macrophages and CD8+ T cells, 
via secretion of pro-inflammatory cytokines, including IFN-γ (95-97). In contrast, Th2 
differentiation requires IL-4 and are involved in the recruitment of eosinophils, mast cells 
and basophils, while also promoting the activation of B cells (96). Th17 arise when the 
cytokine IL-6 and transforming growth factor (TGF-β) are present. Th17 cells secrete IL-17 
and IL-22 and are known to be important in controlling fungal infections (98-100). Treg are 
crucial in the maintenance of peripheral tolerance, by the release of anti-inflammatory 
cytokines such as TGF-β and IL-10 (101). Treg cell population has been specially described 
through their expression of the transcription factor FOXP3, which is critical for the 
development and function of these cells (102, 103). DC promote tolerance by limiting 
effector T cells and promoting Treg differentiation in the periphery through various 
mechanisms including the production of immunosuppressive cytokines such as IL-10, IL-27 
and TGF-β, and the expression of inhibitory molecules such as PD-L1, ILT2, ILT3 and ITL4 
(104-107). In general terms, the interaction between PD-L1 and its receptor PD-1 inhibits 
immune cells activation via induction of apoptosis and T cell anergy (108). Moreover, 
engagement of the inhibitory receptors ILT2, ILT3 and ILT4 reduces the expression of 
costimulatory and antigen-presenting molecules, and inhibits the secretion of cytokines and 
chemokines in DC (109).  
 DC signaling and immunity against Candida albicans 
DC play an important role in controlling mucocutaneous and systemic C. albicans infections 
(110-112). For C. albicans, dimorphism is a key trait involved in the interaction with DC. 
Ingestion of C. albicans yeast cells activates IL-12 production, promoting a priming of Th1 
cells. In contrast, ingestion of hyphae leads to non-protective Th2 priming by suppressing 
IL-12 release and increasing IL-4 production (113). Moreover, immunization of mice with DC 
pulsed with C. albicans yeasts, but not hyphae, reduced the CFU observed in kidneys of C. 
albicans infected mice (113). While Th1 responses are known to be relevant during systemic 
infection, Th17 play an important role during mucocutaneous infection. Th17 cell activation 
by DC is induced by yeast cells in a process mainly dependent on the dectin-1/2-SYK-
CARD9 signaling (99, 111, 114, 115).  
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DC effectively recognize C. albicans through the expression of a wide range of pattern 
recognition receptors (PRR), including the C-type lectin receptors (CLR) dectin-1, dectin-2 
and cell-specific intracellular adhesion molecule-3-grabbing non integrin (DC-SIGN), as well 
as the mannose receptor (MR), Mincle, Galectin-3, TLR2, TLR4, TLR6, and complement 
receptor 3 (CR3). Altogether, these receptors efficiently recognize structural conserved 
moieties expressed on the cell wall of C. albicans, such as β-glucans, phospholipomannan, 
N-linked and O-linked mannans (116-122). However, the CLR dectin-1 and dectin-2 play an 
essential role in morphology-specific recognition of C. albicans. While dectin-1 recognizes 
β-glucan residues mainly expressed in yeast cells, dectin-2 recognizes mannose structures 
present mostly in hyphae forms (123). Although these receptors have certain differences in 
the downstream signaling compared to TLR, they also share common pathways including 
activation of NLRP inflammasomes, MAPK, NF-κB and AP-1 transcription factors, resulting 
in enhanced the expression of costimulatory molecules and secretion of cytokines (Figure 
2) (123-126).  
 
Figure 2. Dectin-1 and dectin-2 signaling pathway 
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Recognition of C. albicans antigens by dectin-1 and dectin-2 leads to phosphorylation of the spleen 
tyrosine kinase (Syk). Syk phosphorylation leads to NF-κB nuclear translocation by removing its 
inhibitor iκB through the IKK complex. Syk can also activate the PLCγ2 signaling leading to PKC 
activation that controls ROS/NLRP3 inflammasome, AP-1 activation via MAPK phosphorylation and 
activation of CARD9/Bcl10/Malt1 complex. The Card9 complex regulates NF-κB activity through the 
iKK complex. Resultant activation of NF-κB and AP-1 leads to expression of cytokines and 
chemokines. Figure modified after (126). 
 
 Nuclear receptors and their role in DC maturation and immune response 
against fungal infections     
3.3.4.1 Nuclear receptors 
Nuclear receptors (NR) are transcription factors activated by lipid-soluble ligands, which 
regulate the expression of several genes involved in diverse processes, including 
differentiation, development, proliferation, metabolism and inflammation (127-130). NR 
transcriptional activity is achieved by a conserved structure consisting of regions with 
specific functions as depicted in figure 3. All NR contain an activation function region 1 (AF-
1), a hypervariable N-terminal region which serves as a target for post-translational 
modifications, such as phosphorylation and SUMOylation, facilitating ligand-independent 
activation function. Furthermore, NR contain a highly conserved DNA-binding domain (DBD) 
which allows the binding to specific DNA sequences known as hormone response element. 
NR ligands bind to the C-terminal region containing the ligand-binding domain (LBD), which 
also mediates dimerization with another NR. Finally, the AF-2 conserved region located near 
the C-terminus regulates ligand-dependent activation of NR, by controlling the binding of 
coactivator and corepressor complexes (127, 128, 130, 131).  
 
Figure 3. Nuclear receptor structure 
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The superfamily of NR is subdivides based on their ligands as “classical” endocrine 
receptors, orphan receptors and adopted orphan receptors (127, 128, 132). Classical 
receptors include the retinoic acid receptor (RAR), vitamin D receptor (VDR), thyroid 
hormone receptors (TR), which are activated by all-trans retinoic acid, 1α25-
dihydroxyvitamin D, and thyroid hormones, respectively (127). In contrast, the ligands for 
orphan receptors are not known. However, several NR became “adopted” following the 
description of several ligands, including peroxisome proliferator activated receptor (PPAR), 
liver X receptor (LXR), farnesoid X receptor (FXR) and retinoid X receptor (RXR), activated 
mainly by metabolites such as fatty acids, oxysterols and bile acids (127, 128, 132).  
One-third of NR form an obligatory heterodimeric partner with RXR and can be further 
classified in two groups depending on the ligand binding properties: permissive and non-
permissive NR. While permissive NR, including PPAR and LXR can be activated either by 
their own ligands or RXR ligands, non-permissive NR, such as RAR, VDR and TR become 
only activated by their own agonists (127, 128). RXR heterodimers are located in the nucleus 
and bind to specific nucleotide sequences, known as hormone response elements, in the 
absence of ligands inhibiting transcriptional activation by the recruitment of corepressor 
molecules (Figure 4A) (127). However, the presence of ligands promotes dissociation of the 
corepressors and recruitment of coactivator complexes necessary for optimal transcriptional 
activity (Figure 4B). Alternatively, some ligands can trigger corepressor molecules 
recruitment, which blocks transcriptional properties of NR (Figure 4C). Finally, other NR 
suppress activation of different transcription factors in a process known as transrepression 
(Figure 4D). Particularly, SUMOylation of PPARγ and LXR triggers their recruitment to 
promotors of inflammatory transcription factors, including NF-κB and activator protein 1 (AP-
1) and physically modulating their activation (127).  
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Figure 4. Nuclear receptor mechanism of action 
Nuclear receptors and its partner, RXR, binds to specific DNA sequences and regulates the 
expression of several genes involved in multiple processes. Nuclear receptors activation is tightly 
regulated by the presence of its ligands. Liganded receptors can recruit co-repressors or co-activator 
complexes to enhance or inhibit gene expression. Alternatively, nuclear receptors might interfere with 
activation of other transcription factors in a process known as transrepression. Figure modified after 
(127). 
 
3.3.4.1.1 Retinoid X receptor: RXR 
Retinoic X receptor (RXR) is a unique member of NR because it forms heterodimers with 
several other NR, most of them requiring RXR as a mandatory partner for DNA binding and 
transcriptional activity. Thus, binding of ligands to permissive RXR heterodimers can 
potentially modify various pathways simultaneously, thereby modulating developmental, 
metabolic and immune processes (127, 133, 134). The most common ligand known is the 
vitamin A metabolite 9-cis retinoic acid (9-cis-RA) which is able to activate all three forms of 
RXR - RXRα, RXRβ and RXRγ (135). Nevertheless, several other synthetic and natural 
agonists have been described (136).  
The regulation of immune function by this receptor was shown in human monocytes-derived 
DC (137). Particularly, activation of RXRα regulates the differentiation process from 
monocytes to DC by altering the expression of costimulatory and antigen-presenting 
molecules, reducing IL-12 release, and increasing IL-10 production in response to LPS 
stimulation (137, 138). Furthermore, activation of RXRα in vivo reduced DC migration to 
draining lymph nodes due to inhibition of CCR7 expression (139). 
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3.3.4.1.2 Retinoic acid receptor: RAR 
Retinoic acid receptor (RAR) mediates all its functions by recognition of the active metabolite 
of vitamin A, all-trans retinoic acid (ATRA), or synthetic ligands which can activate the three 
isoforms – RARα, RARβ and RARγ. RAR plays a crucial role in the regulation of immune 
function, highlighted by higher rates of infections observed in vitamin A deficient patients 
(127, 140-143). RAR forms a non-permissive heterodimer with RXR that binds to the retinoic 
acid response element, consisting of two direct repeats of PuGGTCA spaced by five bases 
(144). Similar to other NR, RAR can interact with several other pathways which highlight its 
relevance in the regulation of multiple processes (145-147).  
Several in vitro and in vivo studies suggested an anti-inflammatory effect of RAR activation 
on innate immune cells (148-150). RAR activation by ATRA or synthetic agonists promotes 
the differentiation of M2 macrophages expressing anti-inflammatory cytokines, while 
suppressing TNF-α and nitric oxide production (148). Moreover, activation of RAR by ATRA 
leads to a repression in IL-12 release via inhibition of NF-κB activation (149, 150).  
RAR is also involved in modulating DC function. Particularly, DC derived from human cord 
blood and differentiated in presence of ATRA are characterized by a reduced IL-12 and 
increased IL-10 secretion (151). Furthermore, DC priming with ATRA enhances the release 
of TGF-β, which promotes expansion of Treg cells, highlighting the importance of ATRA as 
a metabolite with immune-suppressive potential (152, 153). Additionally, treatment of mouse 
splenic DC with ATRA promotes the expression of SOCS3, which attenuates the activation 
of p38 MAPK, and thereby, inhibits the release of IL-12, IL-6 and TNF-α (154). However, in 
presence of pro-inflammatory stimuli, ATRA treatment further increases the maturation of 
DC by activation of NF-κB (155). Interestingly, activation of RAR showed to coordinate 
several genes during the transition from monocytes to DC. Particularly, group 1 of CD1 
genes (CD1a, CD1b and CD1c) was downmodulated, while CD1d showed upregulation 
upon ATRA treatment. Moreover, upregulation of CD1d correlated with an elevated capacity 
to activate invariant Natural Killer T cells (iNKT) (156). Finally, ATRA could be used as an 
adjuvant due to the enhanced DC migration to draining lymph node in a murine model (157).  
Activation of RARα in immune cells modulates infection by pathogenic fungi. In particular, 
ATRA treatment diminished inflammation induced by monocytes infected with C. albicans 
by reducing the surface exposure of Dectin-1 and TLR2, together with a diminished 
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secretion of TNF-α, IL-6 and IL-12. The authors concluded that ATRA administration might 
be useful for prophylactic applications in septic patients infected with C. albicans (158).  
 
3.3.4.1.3 Peroxisome proliferator activated receptors: PPAR 
The family of peroxisome proliferator-activated receptors (PPAR) includes three isoforms: 
PPARα, PPARβ/δ and PPARγ (159). These isoforms differ among each other in their tissue 
expression. PPARα is involved in fatty acid metabolism processes, including β-oxidation 
pathway, fatty acid catabolism, lipogenesis and ketone body synthesis (160). Thereby, 
PPARα is expressed in metabolically active tissues, such as liver, heart, skeletal muscle, 
intestinal mucosa and brown adipose tissue (160, 161). Immune cells including monocytes, 
macrophages and lymphocytes also express this NR (162, 163). Although PPARβ/δ is 
ubiquitously expressed in all organs, it is highly present in the gastrointestinal tract 
(esophagus, liver, and intestines), kidneys and skeletal muscle (164). Similarly, PPARγ is 
expressed in white and brown adipose tissue, the large intestine, spleen, and immune cells, 
most prominently in macrophages and DC (127, 160, 165).  
PPAR have a large cavity binding site, which is approximately 3-4 larger than other NR 
(166). Thereby, PPAR are able to bind several natural and synthetic ligands. In particular, 
PPARγ is activated by natural ligands such as unsaturated fatty acids, 15-hydroxy-
eicosatetraenoic acid, 9- and 13-hydroxy-octadecadienoic acid, 15-deoxy Δ12,14-
prostaglandin J2 and prostaglandin J2 (160, 165). Among synthetic ligands are the insulin 
sensitizers Thiazolidinediones (such as englitazone, ciglitazone, pioglitazonem troglitazone 
and rosiglitazone), non-steroidal anti-inflammatory drugs (i.e. indomethacin, fenoprofen, 
flufenamic acid) and other PPARγ modulators, so-called SPPARMs (Selective PPAR 
modulators) (165).  
PPARγ is known to influence the development and functionality of monocytes and 
macrophages (167-171). Activation of PPARγ suppressed the production of pro-
inflammatory cytokines, such as TNF, IL-6, IL-1β, IL-12, iNOS and MMP-9 in these cells 
(167-170). Interestingly, PPARγ also modulates macrophages migration in response to 
MCP-1, by suppressing CCR2 expression (171). PPARγ inhibits inflammation by physically 
interacting with other transcription factors involved in pro-inflammatory pathways, including 
NF-κB, AP-1, STAT-1 and NFAT, in a process known as transrepression. This process is 
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regulated by SUMOylation of PPARγ, which allows PPARγ to directly interact with the 
transcription factors, thereby preventing the binding to their response elements (172). 
Sequestration of coactivators, signaling through the IL-4 receptor, and altered activation of 
MAPK mediated by PPARγ seems to play an important role in suppressing production of 
inflammatory cytokines (127, 173-175).  
Furthermore, PPARγ is well known to modulate DC functionality by altering the surface 
phenotype, cytokine secretion and T cell activation capacity. Particularly, treatment of DC 
with PPARγ agonists dampens the release of pro-inflammatory cytokines and chemokines, 
including TNF-α, IL-12, IL-5, IL-6, IP-10 (CXCL10) and RANTES (CCL5) (176, 177). 
Moreover, PPARγ activation enhances CD86 while downmodulates CD80 expression (87). 
However, the most important effect was observed in CD1 molecule expression pattern. 
While CD1a is downregulated, CD1d expression increases in PPARγ-instructed DC (87). 
Mechanistically, PPARγ modulates CD1d expression indirectly by enhancing the activity of 
aldehyde dehydrogenase (ALDH1A, RALDH) which is involved in ATRA production. ATRA 
binds to RAR and modulates the expression of CD1d (156). Furthermore, PPARγ activation 
increases the expression of cathepsin D, a lysosomal aspartyl protease, which improves 
lipid antigen processing and loading to the CD1d complex (178).  
PPARγ may play either a beneficial or detrimental role during infection, mainly dependent 
on the pathogen involved (179-181). Majer et al. showed that administration of the synthetic 
PPARγ agonist pioglitazone improves viability of mice infected by C. albicans by 
suppressing neutrophils infiltration into the kidneys of infected mice (182). Furthermore, 
PPARγ activation increases the expression of dectin-1 and MR in macrophages. 
Accordingly, macrophages produce more ROS and have a higher capacity to uptake and 
kill C. albicans (183-185).  
 
3.3.4.1.4 Liver X receptor: LXR 
Liver X receptors (LXR) – namely LXRα and LXRβ - have a large hydrophobic cavity that 
enables the binding of cholesterol and several oxysterols. Thus, this NR play a key role in 
modulating metabolism and cholesterol homeostasis (186). LXR is highly expressed in the 
liver, intestine, adipose tissue, lung, the adrenal glands, kidney, lymphocytes, monocytes, 
macrophages and DC (127, 186). LXR forms a permissive heterodimer with RXR, and binds 
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to specific DNA sequences known as LXR-responsive elements (LXRE), consisting in direct 
repeats of AGTCA separated by 4 nucleotides (187).  
Most of the studies focused on the role of LXR in modulating lipid metabolism. However, 
LXR activity also regulates immune responses, especially in macrophages and DC (188-
192). LXR exerts anti-inflammatory effects in macrophages by inhibiting the expression of 
several pro-inflammatory molecules, such as IL-6, IL-1β, MCP-1, MCP-3, iNOS, and 
cyclooxygenase 2 in response to bacterial or LPS stimulation (193, 194). Similarly as 
PPARγ, LXRα can suppress inflammatory signaling by transrepression which requires 
SUMOylation of the receptor (195). Interestingly, these effects were only observed in short-
term LXR stimulation. Long-term activation of LXR in human macrophages potentiates LPS 
responses, by increasing TLR4 expression, activation of MAPK and ROS production (196). 
The role of LXR in DC biology is conflicting. Geyeregger et al. showed that treatment of 
monocytes with a synthetic LXR ligand impairs DC differentiation and maturation by 
reducing IL-12 and increasing IL-10 secretion (190). Moreover, these cells have a lower 
capacity to activate T-cell, in a process dependent on the reduction of the actin-bundling 
protein fascin (190). However, comprehensive transcriptional and functional analysis 
showed that differentiation of human DC in presence of LXR ligands promotes their capacity 
to activate CD4+ T cells by increasing the expression of costimulatory molecules and pro-
inflammatory cytokines production (IL-12, TNF-α, IL-6 and IL-8), in a process dependent on 
NF-κB activation (191). Interestingly, LXR has a crucial role in DC migration during 
inflammatory conditions due to the regulation of the ectoenzyme CD38 (192, 197).  
Several reports showed that LXR play an important role in modulating the immune response 
against pathogenic bacteria, viruses and parasites (188, 198-202). However, only one report 
has addressed the role of LXR during infection by pathogenic fungi. Bobryshev et al. 
demonstrated that macrophages infected with Chlamydia pneumoniae showed reduction in 
LXRα expression, which correlated with higher formation of foam cells in atherosclerotic 
lesions (203).  
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In summary, NR modulate differentiation and maturation of DC. Furthermore, these 
receptors are involved in the interaction with pathogenic microorganisms. Nevertheless, only 
few reports have addressed the role of these transcription factors during fungal infections. 
Moreover, no study so far has evaluated the potential of microbial products produced by 
pathogenic fungi in modulating immune responses through NR activation.  
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4 Aims of the work 
Farnesol, the first quorum sensing system described in eukaryotes, modulates the hyphae 
to yeast transition in the filamentous fungus C. albicans. However, farnesol also acts as a 
virulence factor during C. albicans infection, by altering immune cells function. Particularly, 
farnesol impairs dendritic cell differentiation and maturation process from monocytes. 
Nevertheless, the molecular mechanisms by which farnesol alters dendritic cell functionality 
remain elusive. In this work, the elucidation of signaling pathways activated by farnesol in 
dendritic cells was investigated.  
The specific aims of this work were:  
 Define molecular pathways modulated by farnesol through the available microarray 
data of dendritic cells differentiated in presence of farnesol 
 Characterize the contribution of nuclear receptors to modulation of dendritic cell 
maturation by farnesol 
 Analyze downstream inflammatory signaling pathways activated by farnesol during 
the maturation process of monocytes to dendritic cells 
 Evaluate the impact of farnesol treatment on the ability of dendritic cells to activate 
different T cells subsets 
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5 Experimental procedures 
5.1 Reagent preparation 
Trans-trans, FOH was obtained as a 4M stock solution (Sigma-Aldrich) and then diluted in 
100% methanol, followed by serial dilutions in RPMI + 5% FBS to the working concentrations 
of 50 µM and 100 µM. Concentrations of FOH were selected based on the observation that 
C. albicans can release up to 55 µM FOH in in vitro culture, and concentrations of 10-250 
µM have been shown to modulate morphology transition in C. albicans (204, 205). The 
following antagonists for nuclear receptors were obtained from Tocris Bioscience: GW9662 
(PPARγ antagonist, 10 µM), AGN193109 (RARα antagonist, 10 µM), GSK2033 (LXRα 
antagonist, 1 µM). Nuclear receptor agonists were: Rosiglitazone (PPARγ agonist, 5 µM, 
Enzo Life Sciences), AM580 (RARα agonist, 100 nM, Sigma-Aldrich) and GW3965 (LXRα 
agonist, 1 µM, Tocris Bioscience). Methanol was used as a solvent control indicated as 
mock-treated DC. Lipopolysaccharide (LPS, Sigma-Aldrich), peptidoglycan (Sigma-Aldrich), 
flagellin (Sigma-Aldrich), zymosan (InvivoGen) and Pam3CSK4 (R&D Systems) were 
diluted in water before application. α-galactosylceramide (α-GalCer) was obtained from 
AbCam and diluted in DMSO.  
5.2 Dendritic cell generation and maturation 
Human monocytes were isolated from buffy coats of healthy volunteers (provided by the 
Transfusion Medicine Department of the University Hospital Jena). First, Peripheral Blood 
Mononuclear Cells (PBMC) were obtained by density gradient centrifugation using 
BIOCOLL (Biochrom AG), and monocytes were positively selected by using anti-CD14-
conjugated beads via a magnetic cell sorting system (MACS) (Miltenyi Biotech). Freshly 
isolated monocytes were resuspended into 6-well plates at a density of 2 x 106 cells per well 
and cultured in RPMI-1640 (Biochrom AG) with 10mM L-glutamine supplemented with 10% 
heat inactivated FBS (Biochrom AG), 800 U/ml GM-CSF (Leukine® Sargamostim) and 1000 
U/ml IL-4 (Miltenyi Biotec). Cells were cultured for 6 days at 37°C and 5% CO2 and half of 
media was changed at day 3. Ligands or solvent control were added to the cell culture 
starting from the first day. NR antagonists were added 1 hour prior FOH or solvent 
stimulation. iDC differentiation was confirmed by CD1a positive and CD14 negative staining. 
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To obtain matured dendritic cells (mDC), iDC were treated with 10 ng/ml LPS (Sigma-
Aldrich) for 24 hours. To block NF-κB and MAPK activation, iDC were pre-incubated for 30 
min prior LPS stimulation with the following inhibitors: SC75741 (NF-κB inhibitor, 5 µM, 
Cayman), SP600125 (JNK inhibitor, 10 µM, InvivoGen), SB203580 (p38 inhibitor, 20 µM, 
InvivoGen), and FR180204 (ERK1/2 inhibitor, 10 µM, Tocris). To evaluate Toll-like receptor 
and dectin-1 activation, iDC were stimulated for 24 hours with the following ligands: 
Pam3CSK4 (TLR 1/2 ligand, 10 µg/ml, R&D systems), peptidoglycan (TLR 2/6 ligand, 10 
µg/ml, Sigma), flagellin (TLR 5 ligand, 100 ng/ml, Sigma) and zymosan (dectin-1 ligand, 100 
µg/ml, InvivoGen) (Figure 5).  
 
 
Figure 5. Generation of monocytes-derived DC 
5.3 Candida albicans cultivation 
Wild-type C. albicans strain SC5314 was maintained on YPD agar. For experiments, cells 
were transferred to M199 medium, pH 4 (9.8 g/l M199, 35.7 g/l HEPES, 2.2 g/l NaHCo3), 
and cultured at 30°C overnight to stationary phase. Germ tubes were induced by culturing 
in M199 medium, pH 8, for one hour at 37°C. Germ tubes were washed with HBSS and 
killed by adding 0.1 % Thimerosal (Sigma-Aldrich) for one hour at 37°C. MOI of 1 was used 
for confrontation assays.  
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5.4 Flow cytometry 
All flow cytometric analyses were performed using the FACSCanto II (BD Bioscience) and 
the data was analyzed with FlowJo 7.6.4 software.  
 Viability determination 
For determination of viability, cells were harvested and stained with Fixable Viability Stain 
V450 (BD Bioscience) for 15 min at room temperature prior cell surface staining. The 
percentage of viable cells (negative staining) was measured. 
 Characterization of cell surface markers 
Phenotypic characterization of DC, iNKT, Th1 and Treg cells was performed by flow 
cytometry using fluorochrome-conjugated antibodies. 100 µl of cell suspension was stained 
with the following antibodies (See table 1). Isotype controls and fluorescence minus one 
(FMO) control were used for proper gating. After 20 min of staining, cells were resuspended 
in CellWash (BD Bioscience) and analyzed immediately on the flow cytometer.  
Antibody/origin Isotype/origin Concentration 
FITC anti-human CD14  Mouse IgG2a/Biolegend 100 µg/ml 
PE anti-human CD1a  Mouse IgG1/Biolegend 50 µg/ml 
PE anti-human CD80  Mouse IgG1/Biolegend 100 µg/ml 
V450 anti-human CD86  Mouse IgG1/BD 
Bioscience 
100 µg/ml 
FITC anti-human CD40  Mouse IgG1/Biolegend 50 µg/ml 
APC anti-human CD1d Mouse IgG/Biolegend 100 µg/ml 
PerCP anti-human HLA-DR Mouse IgG2a/Biolegend 100 µg/ml 
PerCp anti-human CD3 Mouse IgG1/Biolegend 50 µg/ml 
PacificBlue anti-human CD4 Mouse IgG1/Biolegend 100 µg/ml 
PE anti-human CD25 Mouse IgG1/Biolegend 25 µg/ml 
APC anti-human CD85k (ILT3) Mouse IgG1/Biolegend 100 µg/ml 
FITC anti-human CD85j (ILT2) Mouse IgG2b/Biolegend 100 µg/ml 
PE anti-human CD85d (ILT4) Mouse IgG2a/Biolegend 200 µg/ml 
Brilliant Violet 421 anti-human CD274 (PD-
L1) 
Mouse IgG2b/Biolegend 50 µg/ml 
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PE anti-human TLR4 Mouse IgG2a/Biolegend 100 µg/ml 
FITC anti-human 6B11 (anti-Vα24-Jα18) Mouse IgG1/Biolegend 200 µg/ml 
Table 1. Antibodies used for cell surface molecules and intracellular staining analysis 
 
5.5 Invariant Natural Killer T cells expansion 
Autologous T cells were collected by positive selection of CD3+ cells with microbeads 
(Miltenyi Biotec) and stored in DMSO + 90%FBS at -80°C until used in co-culture 
experiments. Mature dendritic cells were generated from primary monocytes as described 
above (Section 5.2). At day 7, mDC were treated with 100 ng/ml of α-GalCer for 24 hours to 
obtain α-GalCer-loaded mDC and were co-cultured with autologous T cells in a 1:10 ratio 
(1x105 mDC : 1x106 T cells) in 24-well plates. 24 hours later, 100 U/ml of recombinant human 
IL-2 (ImmunoTools) was added to induce T cell expansion. After 7 days, iNKT expansion 
was addressed by quantifying CD3+Vα24Jα18+ cells by flow cytometry. For cytokine 
reconstitution assays, recombinant human IL-12 (10 ng/mL) (ImmunoTools) and a mouse 
anti-human IL-10 blocking antibody (10 µg/mL) or a mouse IgG2B isotype control (both 
obtained from R&D systems) were added from the first day of co-culture. At least 5x105 
events were acquired in the flow cytometer. 
5.6 Intracellular staining  
After 7 days of mDC – T cell co-culture, cells were collected and re-stimulated for 6 hours 
with PMA (50 ng/mL) and ionomycin (1 µg/mL), in presence of brefeldin A (5 µg/mL) and 
monensin (5 µg/mL) (Sigma-Aldrich). Intracellular staining of IFN-γ with FITC anti-human 
IFN-γ antibody (Biolegend, concentration: 25 µg/ml) and intracellular fixation and 
permeabilization buffer set according to the manufacturer´s protocol (eBioscience). To 
analyze Treg expansion, cells were fixed and permeabilized with the eBioscience 
FOXP3/Transcription factor staining set, followed by staining with FITC anti-human FOXP3 
(Biolegend, concentration: 80 µg/ml). CD3+IFN-γ+ and CD3+CD25+FOXP3+ cells were 
quantified by flow cytometry. 
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5.7 Phosphoflow 
For experiments analyzing NF-κB and p38 MAPK phosphorylation, 5x105 DC/well were 
seeded into 24-well plates and stimulated with 10 ng/ml LPS for 1 hour, 37°C and 5% CO2. 
To stop the reaction, cells were fixed with intracellular fixation buffer (eBioscience) for 30 
min at RT and permeabilized with 90% freezing methanol overnight. Cells were stained by 
using primary antibodies to phospho-NF-κB p65 (Ser536; clone 93H1) or phospho-p38 
MAPK (Thr180/Tyr182; clone 12F8) (Cell signaling) for 1 hour in the dark at RT followed by 
staining with Dylight649-conjugated donkey anti-rabbit or Dylight488-conjugated donkey 
anti-mouse (Jackson ImmunoResearch) antibodies for 15 min at RT. PBS containing 0,5% 
BSA was used for washing and intracellular staining. Cells were analyzed in the flow 
cytometer. 
5.8 Cytokine measurement 
iDC were incubated in presence of either TLR and dectin-1 ligands for 24 hours, and then 
supernantants were collected and stored at -80 °C. Cytokine concentrations were analyzed 
with the ProcartaPlex immunoassay from ThermoFischer Scientific according to the 
manufacturer´s instructions. 
5.9 RNA isolation and quantitative real-time PCR 
Preparation of whole cell RNA was carried out with the RNeasy Plus Mini Kit (Qiagen) 
according to the manufacturer´s instructions. NanoDrop (ThermoFisher) was used for the 
quantification of the RNA preparations. cDNA was generated from 25 ng of total RNA with 
the Precision nanoScript 2 Reverese transcription kit (Primer Design) and qRT-PCR was 
performed using the PrecisionPLUS MasterMix premixed with SYBRgreen kit (Primer 
Design) and Quantitect Primer Assay oligonucleotides (Qiagen) on a Stratagene Mx3500P 
cycler. Gene expression was normalized to the TBP reference gene and relative expression 
was calculated using the 2-ΔΔCT method.  
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5.10 Statistical analysis 
Data were analyzed with GraphPrism software version 6. Shapiro-Wilk normality test was 
used to assess Gaussian distribution. Comparison among groups was performed using a 
one-way ANOVA with Turkey’s posttest for multiple comparisons. Otherwise, Kruskal-Wallis 
was used as a non-parametric test. Two-tailed unpaired Student´s t test was applied for 
comparison between two groups. P < 0.05 was considered as significant and marked in 
graphs using the following designations: *P < 0.05, **P < 0.01, ***P < 0.001.  
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6 Results 
6.1 Viability of monocyte-differentiated DC in presence of farnesol 
Farnesol (FOH) treatment inhibits proliferation while inducing apoptosis in several type of 
cells (51-57). Thus, Leonhardt et al. performed a viability analysis of iDC with Annexin-V 
and PI staining and showed that FOH treatment during the differentiation process did not 
influence the viability of iDC when used in concentrations up to 50µM, while retaining its 
effects on DC differentiation (56). To confirm this observation, viability of iDC generated in 
presence of FOH was investigated with the use of the fixable viability stain from BD. This 
dye binds to amines which are accessible in permeable cell membranes present in late-
apoptotic/necrotic cells. As shown in figure 6, no differences could be observed in cell 
viability in iDC differentiated in presence of the solvent control or FOH (viable cells: mock-
treated, 94 ± 5 %; with 100 µM FOH, 89 ± 7 %) when compared to untreated cells (94 ± 4 
%). Since we observed no differences in viability for FOH concentrations 50 µM and 100 
µM, subsequent experiments were performed using both FOH concentrations.  
 
Figure 6. Viability of iDC differentiated in presence of FOH 
Monocytes were differentiated into iDC in absence or presence of FOH (50 µM and 100 µM) and 1% 
methanol (mock-treated). Quantitative data of viable cells are shown as means ± SD from 4 
independent experiments using cells from different donors.  
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6.2 Farnesol-differentiated DC have altered activation in response to distinct 
stimulation 
Previous experiments performed by Leonhardt et al. showed that FOH impairs DC 
differentiation from monocytes by altering the surface molecule expression and the secretion 
of Th1-inducing cytokines (56). However, all the demonstrated effects of FOH on mDC so 
far were determined after stimulation of Toll-like receptor 4 (TLR4) signaling by LPS. Thus, 
FOH could be influencing DC maturation by changing the expression pattern of this PRR. 
Nevertheless, the presence of FOH throughout the differentiation and maturation process 
did not modify TLR4 surface expression (Figure 7). To get a broader view regarding the 
impact of FOH, DC were differentiated and stimulated with inactivated C. albicans germ-
tubes and several agonists for Toll-like receptors and dectin-1. Similar to LPS stimulation, 
the expression of costimulatory CD40, CD80, CD86, and the MHC class II molecule HLA-
DR were modulated when cells were exposed to FOH. Differentiation in presence of FOH 
impairs the expression of CD40 and CD80 after every stimulation tested. Moreover, CD86 
surface exposure after LPS stimulation was reduced in FOH-instructed DC compared to the 
mock-treated cells (DC with 100 µM FOH, median of 2865 ± 515; mock-treated DC, median 
of 4589 ± 867, P < 0.01). Interestingly, CD86 surface expression was enhanced in FOH-
differentiated DC when stimulated with Pam3CSK4 (TLR 1/2 agonist) and flagellin (TLR 5 
agonists) (DC with 100 µM FOH: Pam3CSK4, median of 2286 ± 292, P < 0.01; flagellin, 
median of 2135 ± 265, P < 0.001) compared to mock-treated cells (mock-treated DC: 
Pam3CSK4, median of 1245 ± 547; flagellin, median of 819 ± 605). Furthermore, the MHC 
class II HLA-DR molecule was reduced in FOH-differentiated DC after stimulation with C. 
albicans (DC with 100 µM FOH: median of 1186 ± 585, mock-treated DC: median of 2410 ± 
761, P < 0.05) (Figure 8).  
In addition, the release of cytokines and chemokines was altered in FOH-differentiated DC 
in response to Toll-like receptor and dectin-1 ligands (Figure 9). Production of pro-
inflammatory IL-8 and TNF-α was enhanced in FOH-differentiated DC when treated with 
Pam3CSK4 and flagellin compared to mock-treated cells. Furthermore, the release of the 
chemokine MCP-1 (CCL2) and the anti-inflammatory IL-1 receptor antagonist (IL-1RA) was 
increased in FOH-differentiated DC in response to every tested stimulus. Similarly, the 
secretion of anti-inflammatory IL-10 was enhanced in FOH-differentiated DC when treated 
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with Pam3CSK4 and flagellin (DC with 100 µM FOH: Pam3CSK4, 81 ± 72 pg/ml, P < 0.001; 
flagellin, 128 ± 124 pg/ml, P < 0.05) compared to mock-treated cells (mock-treated DC: 
Pam3CSK4, 13 ± 12 pg/ml; flagellin, 10 ± 6 pg/ml). Interestingly, the Th1-inducing cytokine 
IL-12 was reduced in FOH-differentiated DC stimulated with Toll-like receptors and dectin-1 
ligands (DC with 100 µM FOH: LPS, 120 ± 174 pg/ml; P < 0.001; peptidoglycan, 11 ± 16 
pg/ml; P < 0.001) compared to mock-differentiated DC (mock-treated DC: LPS, 3840 ± 1924 
pg/ml; peptidoglycan, 2958 ± 1698 pg/ml). Altogether, these results show that FOH alters 
the differentiation and maturation of DC by modifying the surface expression of key 
molecules and the release of cytokines and chemokines in response to several stimuli, 
indicating that FOH-induced changes are independent of any specific PRR and FOH affects 
downstream signaling cascades.  
  
Figure 7. TLR4 expression in FOH-differentiated iDC and mDC 
Monocytes were differentiated into iDC in the presence or absence of FOH and further stimulated 
with LPS for 24 hours. TLR4 median surface expression was quantified by flow cytometry. 
Quantitative data shown represent means ± SD from 4 independent experiments with cells isolated 
from different donors.  
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Figure 8. CD40, CD80, CD86 and HLA-DR expression in FOH-differentiated DC activated with 
distinct stimuli 
Monocytes were differentiated into iDC in the presence or absence of FOH and further stimulated 
with either LPS (TLR4 agonist), Pam3CSK4 (TLR1/2 agonist), peptidoglycan (TLR2/6 agonist), 
flagellin (TLR5 agonist), Zymosan (Dectin-1 agonist) and C. albicans germ-tubes for 24 hours. For 
each surface marker, median surface expression was quantified by flow cytometry. Quantitative data 
shown represent means ± SD from 4 independent experiments with cells isolated from different 
donors (*P < 0.05; **P < 0.01; ***P < 0.001).  
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Figure 9. Cytokines and chemokines secretion of FOH-differentiated DC in response to distinct 
stimuli 
Monocytes were differentiated into iDC in the presence or absence of FOH and further stimulated 
with either LPS (TLR4 agonist), Pam3CSK4 (TLR1/2 agonist), peptidoglycan (TLR2/6 agonist), 
flagellin (TLR5 agonist), Zymosan (Dectin-1 agonist), inactivated C. albicans for 24 hours. Cytokine 
concentrations were determined by multiplex assay. Data are means ± SD of 4 independent 
experiments using cells isolated from different donors (*P < 0.05; **P < 0.01; ***P < 0.001).  
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6.3 Molecular mechanisms modulated by farnesol on DC differentiation and 
maturation 
 Differentiation of DC in presence of farnesol increased the expression 
of genes involved in nuclear receptor activity 
One of the most prominent effects in DC differentiated in presence of FOH was observed 
for the expression of CD1 transmembrane glycoproteins (56). FOH treatment shifts the 
expression pattern of CD1 molecules. While CD1a was not up-regulated in iDC and mDC, 
CD1d surface exposure was increased (Figure 10A). Consequently, the CD1a/CD1d ratio 
was reduced in FOH-differentiated DC (iDC with 100 µM FOH, ratio of 0.3 ± 0.1) compared 
to the mock-treated cells (mock-treated iDC: ratio of 106 ± 51, P <0.001) (Figure 10B). Since 
expression of CD1 molecules in DC is known to be tightly regulated by the nuclear receptors 
PPARγ and RARα (87, 156), screening of NR and their target genes was performed from 
the transcriptional data available from Leonhardt et al. (56). Several genes linked to NR 
activation, including target genes for PPARγ, RARα, and LXRα were upregulated during DC 
differentiation in presence of FOH (Figure 11A). Quantitative real time PCR was used to 
validate the expression of NR and selected target genes. In accordance with the microarray 
data, FOH induced the expression of PPARγ and its bona fide target gene FABP4 as well 
as LXRα and its target gene APOC1. In addition, the RARα target gene TGM2 was 
upregulated in FOH-differentiated DC. Nevertheless, the expression of the receptor did not 
change during differentiation with FOH. The effects of FOH was concentration-dependent 
and a higher expression of these genes was observed in cells differentiated with 100 µM 
FOH (Figure 11B).  
These results confirmed FOH effects on CD1 molecules - while CD1a showed reduced 
expression, CD1d surface exposure was enhanced. Furthermore, FOH-differentiated DC 
have a higher expression of NR and their target genes.  
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Figure 10. CD1 expression of DC differentiated in presence of FOH 
Surface CD1 molecules expression of iDC and mDC was analyzed by flow cytometry. (A) 
Representative histogram after 6 days of differentiation (iDC) and following LPS stimulation for 24 
hours (mDC). (B) Data shows the ratio between measured expression of CD1a and CD1d on DC 
differentiated with FOH (50 µM and 100 µM), compared to mock-treated DC. The bars show means 
± SD from at least 4 independent experiments. (***P < 0,001, compared to mock-treated DC)  
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Figure 11. Expression of nuclear receptors and their target genes in DC-differentiated in 
presence of FOH.  
(A) Microarray data of immature and mature DC differentiated in absence or presence of FOH (50 
µM) was obtained from Leonhardt et al. and heat map of representative genes was generated. All 
displayed genes have a P value < 0.05 (56). (B) Confirmation of microarray results was performed 
by qRT-PCR. RNA was collected from iDC differentiated in presence or absence of FOH as described 
in experimental procedures. Gene expression was normalized to the TBP reference gene and relative 
expression was calculated using the 2-ΔΔCT method. Data are means ± SD from 3 independent 
experiments using cells from different donors (*P < 0.05; **P < 0.01; ***P < 0.001, compared to mock-
treated DC). 
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6.3.1.1 Activation of PPARγ and RARα leads to a DC phenotype comparable to 
farnesol-differentiated DC 
To evaluate the role of NR activation in the immunophenotypic changes induced by FOH, 
cells were exposed to specific NR agonists and antagonists throughout the process of DC 
differentiation and analyzed for the surface expression of costimulatory and antigen-
presenting molecules. 
Previous reports have shown that activation of NR induce a similar immunophenotype to 
FOH-differentiated DC (87, 156). In agreement with this, the presence of FOH, RSG (PPARγ 
agonist) and AM (RARα agonist) impaired the expression of CD1a after the differentiation 
of monocytes into immature DC (iDC) and after 24 hours of LPS stimulation (mature DC, 
mDC) compared to mock-treated DC (mock-treated iDC, median of 20737 ± 11256, iDC with 
100 µM FOH, median of 144 ± 62, P < 0.001; iDC with RSG, median of 157 ± 38, P < 0.05; 
iDC with AM, median of 274 ± 45, P < 0.001) (Figure 12). Interestingly, expression of CD1d 
was elevated in iDC and mDC in presence of FOH, RSG and AM compared to mock-treated 
cells (mock-treated iDC, median of 255 ± 51, iDC with 100 µM FOH, median of 638 ± 254, 
P < 0.01; iDC with RSG, median of 496 ± 85, P < 0.05; iDC with AM, median of 961 ± 393, 
P < 0.001). No effect was observed when cells were treated with LXRα agonist GW3965. 
Moreover, the expression of the costimulatory molecule CD80 was diminished in iDC and 
mDC treated with FOH, PPARγ and RARα agonists compared to mock-treated cells (mock-
treated mDC, median of 1565 ± 390, mDC with FOH 100µM, median of 725 ± 212, P < 
0.001; mDC with RSG, median of 951 ± 370, P < 0.05; mDC with AM, median of 819 ± 123, 
P < 0.01). In contrast, the expression of the costimulatory molecule CD86 was increased in 
iDC differentiated with FOH and agonists for PPARγ and RARα compared to mock-treated 
cells (mock-treated iDC, median of 139 ± 30, iDC with FOH 100µM, median of 732 ± 284, P 
< 0.05; iDC with RSG, median of 2334 ± 1265, P < 0.001; iDC with AM, median of 1181 ± 
352, P < 0.01). No differences in CD86 expression were observed after LPS stimulation. 
These results showed that differentiation of DC in the presence of PPARγ and RARα 
agonists lead to a similar immunophenotype of DC compared to FOH-differentiated cells.  
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Figure 12. Surface molecules expression on DC differentiated in presence of farnesol and 
nuclear receptors agonists 
Monocytes were differentiated into DC in the presence or absence of 50 µM or 100 µM FOH and 
nuclear receptors agonists. For each surface marker, median surface expression after 6 days of 
differentiation (iDC) and 24 hours stimulation with LPS (mDC) was quantified by flow cytometry. 
Quantitative data shown represent means ± SD from at least 3 independent experiments with cells 
isolated from different donors (*P < 0.05; **P < 0.01; ***P < 0.001, compared to mock-treated DC). 
RSG: PPARγ agonist Rosiglitazone; AM: RARα agonist AM580; GW: LXRα agonist GW3965. 
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6.3.1.2 Nuclear receptor inhibitors have no significant effect on dendritic cell 
viability 
DC were differentiated from monocytes in presence of previously published concentration 
of NR antagonists and viability was determined by flow cytometry. As shown in the figure 
13, the presence or absence of FOH and NR antagonists during the differentiation process 
did not alter DC viability. Thus, subsequent experiments were performed by using these 
concentrations of FOH and NR antagonists. 
 
Figure 13. Viability of DC differentiated with nuclear receptor antagonists 
Discrimination of viable from non-viable cells was evaluated by flow cytometry. Dead cells were 
identified by positive staining with the Fixable Viability Stain V450. Data are means ± SD from 3 
independent experiments using cells isolated from different donors. PPARγ antagonist: GW9662, 
RARα antagonist: AGN193109, LXRα antagonist: GSK2033, RXR antagonist: HX531.  
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6.3.1.3 Farnesol modulates DC phenotype partially through activation of the PPARγ 
and RARα signaling pathways 
DC generated in the presence of FOH were characterized by markedly lower surface 
expression of CD1a, but an increased expression of CD1d (Figures 10 and 12). to evaluate 
the role of nuclear receptor activation in the immunophenotypic changes induced by FOH, 
cells were exposed to various nuclear receptors antagonists during DC differentiation and 
analyzed for their surface expression of costimulatory and antigen-presenting molecules. 
The combination of FOH and NR antagonists were not enough to recover CD1a expression 
(Figure 14). In contrast, blocking the activity of PPARγ with the PPARγ antagonist GW9662 
in iDC differentiated with 50 µM and 100 µM FOH returned CD1d expression to basal levels 
(mock-treated iDC, median of 266 ± 70; iDC with 50 µM FOH, median of 481 ± 145; iDC 
with 50 µM FOH and PPARγ antagonist, median of 265 ± 53). A similar return to basal CD1d 
expression levels DC was observed in the presence of RARα antagonist AGN193109 
(mock-treated iDC, median of 289 ± 71; iDC with 50 µM FOH, median of 474 ± 149; iDC 
with 50 µM FOH and RARα antagonist, median of 243 ± 64). These effects were also 
maintained during the maturation process from iDC to mDC, suggesting that the increased 
CD1d surface exposure induced by FOH is regulated by a common pathway that involves 
both receptors. The use of LXRα antagonist affected neither CD1a nor CD1d surface 
expression during FOH treatment. However, blocking LXRα receptor activity downregulated 
CD1a expression (mock-treated iDC, median of 12731 ± 6598; with LXRα antagonist, 
median of 2845 ± 2469) and promoted the surface expression of CD1d (mock-treated iDC, 
median of 259 ± 85; with LXRα antagonist, median of 581 ± 203) in mock-treated control 
cells comparable to the effects induced by FOH (iDC with 50 µM FOH: CD1a, median of 
255 ± 98; CD1d, median of 525 ± 227). To confirm the role of NR in the regulation of CD1 
molecules by FOH, cells were differentiated in presence of an antagonist for RXRα, which 
serve as a partner for these receptors and are known to be essential for their functionality 
(127). Downmodulation of CD1a expression by FOH was not restored in presence of RXRα 
antagonist (Figure 15). Nevertheless, CD1d upregulation in FOH-instructed DC was blocked 
when the antagonist was present after the differentiation process (iDC with 100 µM FOH, 
median of 400 ± 81; with 100 µM FOH and RXRα antagonist, median of 241 ± 30, P < 0.05), 
reaching levels observed in mock-treated cells (mock-treated iDC, median of 202 ± 53).  
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Figure 14. CD1 molecule expression induced by FOH in presence of nuclear receptor 
antagonists 
Monocytes were differentiated into DC in the presence of either 50 µM or 100 µM FOH or mock 
treatment and the nuclear receptors antagonists indicated. For both surface markers, median surface 
expression after 6 days of differentiation (iDC) and 24 hours stimulation with LPS (mDC) was 
quantified by flow cytometry. Quantitative data shown represent means ± SD from at least 5 
independent experiments with cells isolated from different donors (*P < 0.05; **P < 0.01; ***P < 
0.001). PPARγ antagonist: GW9662, RARα antagonist: AGN193109, LXRα antagonist: GSK2033, 
RXR antagonist: HX531. 
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Figure 15. CD1 molecule expression induced by FOH in presence of RXRα antagonist 
Monocytes were differentiated into DC in the presence of either 50 µM or 100 µM FOH or mock 
treatment and the RXR antagonist. For both surface markers, median surface expression after 6 days 
of differentiation (iDC) and 24 hours stimulation with LPS (mDC) was quantified by flow cytometry. 
Quantitative data shown represent means ± SD from 4 independent experiments with cells isolated 
from different donors (*P < 0.05; **P < 0.01; ***P < 0.001). RXRα antagonist: HX531. 
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To fully characterize the role of NR on the impact of FOH over DC differentiation and 
maturation, the expression of costimulatory and antigen-presenting molecules, which play a 
key role in DC functionality, was analyzed by flow cytometry. CD80 and CD40 expression 
was reduced in FOH-differentiated iDC and mDC (Figure 16). Nevertheless, the presence 
of PPARγ antagonist partially blocked CD80 downmodulation by lower FOH concentration 
in iDC (iDC with 50 µM FOH, median of 276 ± 65; iDC with 50 µM FOH and PPARγ 
antagonist, median of 454 ± 120, P < 0.05) and reached levels similar to mock-treated DC 
(median of 385 ± 140). In contrast, CD86 was upregulated in cells differentiated with FOH 
and the presence of PPARγ antagonist blocked this effect (mock-treated iDC, median of 202 
± 79, iDC with 50 µM FOH, median of 505 ± 207, iDC with 50 µM FOH and RARα antagonist, 
median of 242 ± 80, P < 0.05). Similarly, the presence of RARα antagonist blocked the 
upregulation of CD86 induced by FOH treatment (Figure 17). Interestingly, CD86 expression 
was partially down-modulated in presence of FOH after LPS stimulation and this effect was 
blocked during treatment with PPARγ antagonist. Finally, no significant differences were 
observed in HLA-DR expression after differentiation in presence of FOH. Nevertheless, 
HLA-DR expression was diminished in FOH-differentiated DC after LPS stimulation with no 
significant effects observed in presence of NR antagonists (mock-treated mDC: median of 
3669 ± 213, mDC with 100µM FOH, median of 2360 ± 994, P < 0.05).  
Altogether, these results confirmed alterations in the immunophenotype of DC differentiated 
in the presence of FOH. Even though altered expression of CD1a, CD40 and HLA-DR 
induced by FOH could not be restored by treatment with different NR antagonists, the altered 
expression of CD1d, CD80 and CD86 observed after differentiation was partially dependent 
on PPARγ and RARα activation.  
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Figure 16. CD80 and CD40 molecule expression modulated by FOH in presence of nuclear 
receptors antagonists 
Monocytes were differentiated into DC in the presence of either 50 µM or 100 µM FOH or mock 
treatment and the nuclear receptor antagonists indicated. For each surface marker, median surface 
expression after 6 days of differentiation (iDC) and 24 hours stimulation with LPS (mDC) was 
quantified by flow cytometry. Quantitative data shown represent means ± SD from at least 5 
independent experiments with cells isolated from different donors (*P < 0.05; **P < 0.01; ***P < 
0.001). PPARγ antagonist: GW9662, RARα antagonist: AGN193109, LXRα antagonist: GSK2033. 
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Figure 17. CD86 and HLA-DR molecule expression modulated by FOH in presence of nuclear 
receptors antagonists 
Monocytes were differentiated into DC in the presence of either 50 µM or 100 µM FOH or mock 
treatment and the nuclear receptor antagonists indicated. For each surface marker, median surface 
expression after 6 days of differentiation (iDC) and 24 hours stimulation with LPS (mDC) was 
quantified by flow cytometry. Quantitative data shown represent means ± SD from at least 5 
independent experiments with cells isolated from different donors (*P < 0.05; **P < 0.01; ***P < 
0.001). PPARγ antagonist: GW9662, RARα antagonist: AGN193109, LXRα antagonist: GSK2033. 
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6.3.1.4 Release of cytokines and chemokines by farnesol-differentiated DC is mainly 
independent of nuclear receptors activation 
The release of cytokines and chemokines by DC play an important role in regulating T cell 
activation. Cells were differentiated in presence or absence of NR antagonists and then 
stimulated with LPS to test the contribution of NR activity in the secretion of cytokines and 
chemokines (Figure 18). IL-8 and MCP-1 (CCL2) secretion was enhanced in FOH-
differentiated DC and not influenced by NR antagonists. Interestingly, the FOH-induced 
increased secretion of pro-inflammatory TNF-α was blocked in presence of LXRα antagonist 
(100 µM FOH: without LXRα antagonist, 8.7 ± 3.5 ng/ml; with LXRα antagonist, 
3.0 ± 1.4 ng/ml, P < 0.05) and restored TNFα levels to those observed in mock-treated DC 
(4.4 ± 1.0 ng/ml). In contrast, cells treated with RARα antagonist showed a reduction in TNF-
α in every tested condition, suggesting a general and FOH-independent effect. Interestingly, 
differentiation of DC with either PPARγ, RARα or LXRα antagonists in the absence of FOH 
resulted in elevated levels of the anti-inflammatory cytokine IL-10, and synergistically 
increased its release in cells differentiated with 50 µM FOH. However, IL-10 release induced 
by higher concentration of FOH was not further enhanced by blocked NR activities. In 
contrast, the release of RANTES was dampened in FOH-instructed DC in a concentration-
dependent manner and the presence of PPARγ antagonist partially increases the release of 
this chemokine in every tested condition. Moreover, IL-12 secretion was impaired in FOH-
differentiated DC and treatment with the respective antagonists was not sufficient to restore 
the secretion of this cytokine by mDC. Treatment with the LXRα antagonist alone inhibited 
IL-12 secretion in mock-treated mDC and during exposure to the lower FOH concentration.  
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Figure 18. Cytokines and chemokines release by DC differentiated in presence of FOH and NR 
antagonists 
Supernatants were collected after stimulation of iDC that were differentiated either in the absence or 
presence of FOH (50 µM and 100 µM) for 24 hours with LPS. Nuclear receptor activities were blocked 
using the respective antagonists: PPARγ antagonist GW9662; RARα antagonist AGN193109; LXRα 
antagonist GSK2033. Cytokine and chemokines concentrations were determined by multiplex assay. 
Data are means ± SD of 4 independent experiments using cells isolated from different donors (*P 
< 0.05; **P < 0.01; ***P < 0.001). 
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 Role of MAPK and NF-κB signaling cascades in farnesol-differentiated 
DC 
Pathway analysis of differentially expressed genes revealed that numerous processes were 
influenced by FOH stimulation, including antigen processing and presentation, PPAR 
signaling pathways, cytokine-cytokine interaction, and NF-κB signaling (56). In particular, 
activation of MAPK and NF-κB signaling pathways is known to be essential for proper 
differentiation and maturation of DC from monocytes (74, 75, 78, 79). To obtain further 
insights of the molecular mechanisms that regulate the altered maturation of DC, cell surface 
markers and cytokines release were measured from iDC treated with specific NF-κB and 
MAPK inhibitors prior stimulation with LPS.  
6.3.2.1 MAPK and NF-κB signaling pathways modulate maturation of DC 
Treatment of DC with MAPK and NF-κB inhibitors did not restore CD1a downregulation in 
FOH-differentiated DC (Figure 19). Interestingly, upregulation of CD1d by FOH was partially 
blocked in presence of p38 inhibitor (mDC with 100 µM FOH, median of 473 ± 84; mDC with 
100 µM FOH and p38 inhibitor, median of 341 ± 52, p: 0.07). As expected, the upregulation 
of CD80 by LPS stimulation was significantly blocked in the presence of p38 MAPK and NF-
κB inhibitors (mock-treated mDC, median of 1102 ± 165; with NF-κB inhibitor, median of 
778 ± 171, P < 0.01; with p38 inhibitor, median of 645 ± 100, P < 0.001). Moreover, during 
FOH treatment we observed a synergistic reduction on the expression of CD80 in the 
presence of p38 MAPK and NF-κB inhibitors (mDC with 50 µM FOH, median of 810 ± 168; 
mDC with 50 µM FOH and NF-κB inhibitor, median of 559 ± 150, P < 0.05; mDC with 50 µM 
FOH and p38 inhibitor, median of 409 ± 86, P < 0.001). In contrast, CD40 and CD86 surface 
exposure in DC-differentiated in absence or presence of FOH was blocked only in the 
presence of the NF-κB inhibitor. Finally, the surface exposure of HLA-DR was not affected 
in any of the conditions tested.  
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Figure 19. Surface molecule expression in FOH-differentiated mDC in presence of MAPK and 
NF-κB inhibitors 
Monocytes were differentiated into iDC in the presence of either 50 µM or 100 µM FOH or mock 
treatment followed by stimulation with LPS for 24 hours. For each surface marker, median surface 
was quantified by flow cytometry. Quantitative data represent means ± SD from 3 independent 
experiments with cells isolated from different donors (*P < 0.05; **P < 0.01; ***P < 0.001). MAPK and 
NF-κB activation were blocked using respective antagonists: SC75741: NF-κB inhibitor, SP600125: 
JNK inhibitor, SB203580: p38 inhibitor, FR180204: ERK1/2 inhibitor. 
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6.3.2.2 Farnesol regulates cytokine and chemokine secretion through MAPK and NF-
κB signaling pathways 
Our previous results showed that FOH modulate the expression CD1d and costimulatory 
molecules through activation of NF-κB and p38 MAPK. Thereby, we proceeded our analysis 
by measuring the release of cytokines and chemokines in DC differentiated in presence or 
absence of FOH, NF-κB and MAPK inhibitors. Even though the release of IL-8 was not 
blocked by any of the inhibitors tested (Figure 20), the presence of NF-κB inhibitor blocked 
the enhanced release of MCP-1, TNF-α and IL-10 induced by FOH. Interestingly, treatment 
with JNK and p38 MAPK inhibitors impaired the elevated secretion of TNF-α and IL-10 
induced by FOH, respectively. Moreover, reduction in RANTES secretion was observed in 
presence of NF-κB, JNK and p38 inhibitors in every tested condition. Similarly, NF-κB and 
p38 signaling pathways also regulated IL-12 release in mock-treated mDC (mock-treated 
mDC, 3217 ± 1379 pg/ml; mock-treated mDC with NF-κB inhibitor, 1206 ± 796 pg/ml, P < 
0.05; mock-treated mDC with p38 inhibitor, 61 ± 24 pg/ml, P < 0.001). In contrast, during 
FOH treatment a synergistic reduction was observed in the presence of the p38 inhibitor 
(50 µM FOH, 402 ± 221 pg/ml; 50 µM FOH and p38 inhibitor, 27 ± 13 pg/ml). To confirm if 
FOH treatment modify the activation of these signaling pathways, phosphorylation levels of 
p65-NF-κB and p38 MAPK was evaluated through flow cytometry. PhosphoFlow analysis 
showed that iDC differentiated in the presence of FOH have a higher activation of NF-κB 
compared to mock-treated DC (0 min with 100 µM FOH, fold change of 3 ± 0.3; without 100 
µM FOH, fold change of 2.5 ± 0.4, P < 0.05) (Figure 21). As expected, phosphorylation of 
p65 increased after 60 min of LPS stimulation in mock-treated DC, but no differences were 
observed compared to FOH-differentiated DC. Finally, DC differentiated in presence of 100 
µM FOH showed an enhanced p38 phosphorylation compared to mock-treated DC before 
and after 60 min of LPS stimulation (Figure 22). Altogether, these results indicate that FOH 
modulates activation of MAPK and NF-κB signaling pathways which results in altered 
expression of costimulatory molecules and cytokine release.  
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Figure 20. Cytokine and chemokine release by DC differentiated in presence of FOH and NF-
κB and MAPK pathway inhibitors 
iDC were differentiated either in the absence or presence of FOH (50 µM and 100 µM), stimulated 
with LPS for 24 hours, and then supernatants were collected. MAPK and NF-κB activation were 
blocked using respective antagonists: SC75741: NF-κB inhibitor, SP600125: JNK inhibitor, 
SB203580: p38 inhibitor, FR180204: ERK1/2 inhibitor. Cytokine concentrations were determined by 
multiplex assay. Data are means ± SD of 3 independent experiments using cells isolated from 
different donors (*P < 0.05; **P < 0.01; ***P < 0.001). 
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Figure 21. Analysis of NF-κB activation in FOH-differentiated mDC 
iDC were differentiated either in the absence (mock-treated) or presence of FOH (100 µM) and 
phosphorylation of p65 NF-κB was addressed through flow cytometry. Figure shows representative 
histogram of p38 phosphorylation followed by statistical analysis of DC before (A) and after 60 min of 
LPS stimulation (B). Quantitative analysis is from 4 independent experiments with cells isolated from 
different donors and shown as fold change values acquired between DC-differentiated in absence or 
presence of FOH and normalized to values observed in unstained DC (*P < 0.05). 
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Figure 22. Analysis of p38 activation in FOH-differentiated mDC 
iDC were differentiated either in the absence (mock-treated) or presence of FOH (100 µM) and 
phosphorylation of p38 MAPK was addressed through flow cytometry. Figure shows representative 
histogram of p38 phosphorylation followed by statistical analysis of DC before (A) and after 60 min of 
LPS stimulation (B). Quantitative analysis is from 4 independent experiments with cells isolated from 
different donors and shown as fold change values acquired between DC-differentiated in absence or 
presence of FOH and normalized to values observed in unstained DC (*P < 0.05). 
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6.4 Functional impact of farnesol treatment in DC 
DC play an important role in orchestrating immune response through antigen-presentation 
and activation of effector T cells (65). Consequently, alteration of these functions might have 
important consequences in the ability to overcome infection by pathogenic microorganisms. 
To evaluate if FOH treatment alters DC capacity to activate T cells, mDC and T cell co-
cultures were performed and the ability of mDC to activate iNKT, Th1 and Treg was 
adressed by flow cytometry.  
 Farnesol-differentiated DC have a lower capacity to activate iNKT and 
Th1 cells 
The previous results showed that FOH alters dramatically the expression of CD1d molecules 
through PPARγ, RARα and partially through p38 MAPK activation. CD1d is a major-
histocompatibility-complex (MHC) class-1-like molecule that presents lipid antigens to 
invariant Natural Killer T (iNKT) cells to activate them (85, 87). To test whether the elevated 
CD1d surface levels induced by FOH would correlate with an increased capability of mDC 
to induce iNKT activation, expansion of iNKT cells was analyzed by flow cytometry. 
Surprisingly, iNKT proliferation was reduced in the presence of FOH-differentiated mDC 
(50 µM FOH, fold change of 2.5 ± 1.2, P < 0.01) compared to the mock-treated mDC (Fold 
change of 7.3 ± 1.7), regardless of their significantly enhanced CD1d levels (Figure 23). 
Although CD1d expression induced by FOH was dependent on both PPARγ and RARα 
activity, blocking NR activities resulted in comparably low iNKT expansion. 
All data reported so far suggest that FOH-differentiated mDC have a defect to induce proper 
T cell responses, by reducing the expression of costimulatory molecules and the MHC class 
II molecule HLA-DR. To evaluate if FOH alters the capacity of mDC to activate Th1 cells, 
mDC differentiated in presence or absence of FOH and NR antagonists were co-cultured 
with autologous T cells for 7 days and IFN-γ production was analyzed by flow cytometry 
after restimulation with PMA/ionomycin. As expected, T cells co-cultured with mock-treated 
mDC (Fold change of 16.6 ± 5.4) have a higher ability to induce IFN-γ production compared 
to FOH differentiated mDC (50 µM FOH, fold change of 5.2 ± 2.7, P < 0.05) (Figure 24). The 
presence of specific antagonists for PPARγ and RARα did not restore the capability of mDC 
to induce IFN-γ production by T cells.  
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Figure 23. iNKT expansion by FOH treated-DC 
Autologous T cells were co-cultured with mDC for 7 days. iNKT expansion was measured by flow 
cytometry and quantitative analysis from 4 independent experiments with cells isolated from different 
donors is displayed. Quantitative analysis is shown as means ± SD of fold change values acquired 
between % iNKT cells of total T cells in co-culture with mock- or FOH-treated mDC normalized to 
values observed in T cells cultured without mDC (*P < 0.05; **P < 0.01). GW: PPARγ antagonist 
GW9662; AGN: RARα antagonist AGN193109. 
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Figure 24. IFN-γ production by T cells co-cultured with mDC 
Autologous T cells were co-cultured with mDC for 7 days. T cells were collected and re-stimulated 
with PMA (50 ng/mL) and ionomycin (1 µg/mL), in the presence of brefeldin A (5 µg/mL) and monensin 
(5 µg/mL) for 6 hours. IFN-γ production was analyzed by intracellular staining and flow cytometry. 
Quantitative analysis of 3 independent experiments is shown as means ± SD of fold change values 
acquired between % IFN-γ+ cells of total T cells co-culture with mock- or FOH-treated mDC 
normalized to values observed in T cells cultured without mDC (*P < 0.05; **P < 0.01). PPARγ 
antagonist: GW9662; RARα antagonist: AGN193109. 
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6.4.1.1 Altered secretion of IL-12 and IL-10 influences the capacity of farnesol-
differentiated DC to activate different T cell subsets 
Although FOH increased CD1d expression in DC, no positive effect was observed in their 
capacity to induce iNKT expansion. A possible explanation could be the increased IL-10 
secretion and reduced IL-12 release observed in FOH-treated mDC. Due to their potent 
effect on activating T cells, IL-12 family members are an important link between innate and 
adaptive immunity. Moreover, IL-10 is known to inhibit IL-12 production by macrophages 
and DC (206). To test if the shift in the IL-12/IL-10 ratio observed in FOH-differentiated DC 
might play a role in iNKT activation (Figure 25A), T cell-mDC co-culture experiments were 
performed in the presence of increased IL-12 levels by addition of recombinant IL-12, while 
IL-10 activity was reduced by the use of blocking antibody. Interestingly, the reduced iNKT 
proliferation observed in presence of FOH-differentiated DC was increased after 
reconstitution of the IL-12/IL-10 milieu by addition of recombinant IL-12 and neutralizing αIL-
10, reaching levels similar to the mock T cell-mDC co-culture (mock-treated mDC, fold 
change of 10.1 ± 3.7, with 50 µM FOH, fold change of 4.7 ± 2.9; 50 µM FOH and IL-12/αIL-
10, fold change of 12.1 ± 4.8, P < 0.05) (Figure 25B). Furthermore, addition of recombinant 
IL-12 and αIL-10 also enhanced iNKT proliferation in mock T cell-mDC co-culture (Fold 
change of 15.4 ± 3.8).  
To test if the altered IL-12 and IL-10 release also played a role in mDC capability to induce 
IFN-γ production by T cells, co-culture of mDC and autologous T cells for 7 days was 
performed and IFN-γ production by T cells was induced by restimulation with 
PMA/ionomycin (Figure 26). In line with the result observed for iNKT expansion, the reduced 
percentage of IFN-γ producing T cells co-cultured with FOH-differentiated mDC was 
restored to levels observed in mock-treated mDC co-culture (Fold change of 6.8 ± 4.9) when 
elevated concentrations of IL-12 and IL-10 blocking antibody were present (50 µM FOH, fold 
change of 1.3 ± 0.3; 50 µM FOH and IL-12/αIL-10, fold change of 6.7 ± 4.8, P < 0.05).  
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Figure 25. Diminished capacity to induce iNKT expansion by FOH-differentiated mDC is 
dependent on the altered secretion of IL-12 and IL-10 
iDC were differentiated either in the absence or presence of FOH (50 µM and 100 µM), stimulated 
with LPS for 24 hours, and then supernatants were collected. (A) Data show the ratio between the 
measured concentrations of IL-12 and IL-10. (B) iNKT expansion was analyzed by flow cytometry 
after 7 days of co-culture with mock-treated or FOH-instructed mDC in the presence of recombinant 
IL-12 and anti-IL-10 mAb or the respective isotype control. Bars are means ± SD from 4 independent 
experiments using cells isolated from different donors and show fold change values acquired between 
% iNKT cells of total T cells in co-culture with mock- or FOH-treated mDC normalized to values 
observed in T cells cultured without mDC (*P < 0.05; **P < 0.01, ***P < 0.001).  
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Figure 26. Altered release of IL-12 and IL-10 by FOH-treated mDC impacts their capacity to 
induce T helper 1 polarization 
Autologous T cells were co-cultured with mock-treated or FOH-differentiated mDC in presence or 
absence of IL-12 and anti-IL-10 mAb, or an isotype control, and IFNγ production by T cells was 
evaluated after 7 days of co-culture. Bars are means ± SD from 4 independent experiments using 
cells isolated from different donors and show fold change values between % IFNγ+ T cells of total T 
cells in co-culture with mock- or FOH-treated mDC and normalized to values observed in T cells 
cultured without mDC (*P < 0.05). 
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 Farnesol-differentiated DC have a higher expression of inhibitory 
receptors but lack capacity to induce regulatory T cells expansion 
The low expression of costimulatory molecules, together with a higher secretion of IL-10 and 
reduced capacity of FOH-differentiated mDC to activate iNKT and Th1 cells, might indicate 
that FOH treatment shift DC functionality towards a tolerogenic phenotype. Therefore, 
analysis of inhibitory receptors expression, including Ig-like transcripts (ILTs, also called 
leukocyte Ig-like receptors) ILT2, ILT3, ILT4, and programmed cell death 1 ligand 1 (PD-L1), 
known to be a hallmark of tolerogenic DC (107, 109), was performed by flow cytometry after 
differentiation and 24 hours LPS stimulation. The expression of ILT2 and ILT4 was not 
influenced by FOH (Figure 27). Nevertheless, increased surface exposure of ILT3 after LPS 
stimulation was evidenced in FOH-differentiated mDC compared to mock-treated cells 
(mDC with 100 µM FOH, median of 12000 ± 1032, mock-treated mDC, median of 3716 ± 
549; P < 0.001) Similarly, expression of PD-L1 was enhanced in mDC differentiated in 
presence of FOH (mDC with 100 µM FOH, median of 4740 ± 151; mock-treated mDC, 
median of 3136 ± 482; P < 0.001). Elevated expression of inhibitory receptors and IL-10 
secretion was hypothesized to enhance the capacity to activate FOXP3+ Treg cells (104, 
207). Thereby, T cells were co-cultured with mDC differentiated in absence or presence of 
FOH and Treg cells expansion was evaluated after 7 days. Interestingly, the enhanced 
expression of inhibitory receptors in FOH-differentiated mDC did not lead to elevated Treg 
cells expansion compared to mock-treated mDC (mDC with 100 µM FOH, fold change 1.8 
± 1.5; mock-treated mDC, fold change 13.6 ± 10.5) (Figure 28). In line with our previous 
results, the addition of recombinant IL-12 and IL-10 blocking antibody restored FOH-
differentiated DC capacity to activate Treg cells to comparable levels observed in mock-
treated mDC co-culture (mDC with 100 µM FOH and IL-12/αIL-10, fold change 11.6 ± 6.5).  
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Figure 27. FOH enhances the surface expression of inhibitory receptors on mDC 
Monocytes were differentiated into iDC in the presence or absence of FOH followed by a 24 hours 
LPS stimulation to generate mDC. The expression of ILT2, ILT3, ILT4 and PD-L1 was analyzed by 
flow cytometry. Quantitative data are means ± SD from at least 4 independent experiments with cells 
isolated from different donors (***P < 0.001 compared to mock-treated).   
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Figure 28. FOH altered DC capacity to induce FOXP3+ regulatory T cells expansion 
Autologous T cells were co-cultured with mDC for 7 days in the absence or presence of recombinant 
IL-12 and anti-IL-10 mAb, or the respective isotype control and CD4+CD25+FOXP3+ Treg cells 
expansion was measured by flow cytometry. Quantitative data are means ± SD from 4 independent 
experiments with cells isolated from different donors (***P < 0.001).   
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7 Discussion  
QS systems coordinate the expression of genes involved in several processes, including 
virulence in pathogenic microorganisms (15, 208). FOH is the first QS molecule described 
in a eukaryotic microorganism, and its role in modulating filamentation in C. albicans is well 
understood (27-32). Similarly, FOH has been shown to regulate functionality of innate 
immune cells, such as neutrophils, monocytes, macrophages and dendritic cells. Leonhardt 
et al. showed that FOH has a profound impact on dendritic cells differentiation from 
monocytes, while suppressing their capacity to induce T cell proliferation. However, the 
molecular basis behind these effects is poorly understood (56).  
The aim of this study was to analyze the signaling pathways modulated by FOH during 
dendritic cells differentiation, and its impact on their function.  
7.1 Farnesol impairs DC differentiation and maturation partially through 
nuclear receptors activation 
Leonhardt et al. found that FOH restrict the differentiation from monocytes to DC, by 
retaining the expression of the monocyte marker CD14 while impairing costimulatory 
molecules surface exposure and T cell activation capacity (56). This study confirmed that 
FOH blocked maturation of DC by modifying the expression of costimulatory and antigen-
presenting molecules, as well as the release of cytokines and chemokines in response to C. 
albicans germ tubes and several ligands to Toll-like receptors and dectin-1. These results 
suggest that FOH-induced changes are not dependent of any specific surface receptor and 
affect intracellular signaling cascades. Pathway analysis of differentially expressed genes 
during DC differentiation identified several intracellular processes that were modified in 
presence of FOH, including the PPAR signaling pathway (56). In agreement, transcriptional 
analysis revealed that several target genes associated to activation of NR PPARγ, RARα 
and LXRα were upregulated. Moreover, differentiation of DC in presence of specific ligands 
for these NR showed a similar phenotype compared to FOH-treated DC. Furthermore, the 
presence of PPARγ and RARα antagonists blocked upregulation of CD1d by FOH-
treatment, and partially reverted FOH effect on CD80 and CD86 surface molecules 
expression and the release of the chemokine RANTES. Interestingly, RARα and LXRα 
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showed to have a major role in the release of pro-inflammatory TNF-α induced by FOH. 
While these results suggest that FOH activates NR, it is not clear how these cells sense 
FOH in the environment. On the one hand, FOH could be interacting directly with NR as 
suggested by nuclear localization of a fluorescent analog (20). On the other hand, FOH can 
be metabolized into farnesyl-PP, an intermediate of the mevalonate/cholesterol biosynthetic 
pathway, which can be further transformed into NR ligands (209). However, Shchepin et al. 
showed that the mode of action of FOH is specific, since changes in its structure blocked its 
biological activity (20). Interestingly, FOH is not the only QS molecule known to affect DC 
differentiation. Treatment of DC with the bacterial QS molecule homoserine lactone 
diminished the expression of the costimulatory molecules CD80 and CD86 (210). 
Interestingly, the effect of QS molecules on DC differentiation could have an important 
impact on septic patients. Boontham et al. showed that homoserine lactone effects on DC 
function correlated with elevated presence of this QS molecule in sera of septic patients 
(211). Although it is not known the role of FOH during sepsis, Ryan et al. showed that 
monocyte-derived DC from autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy (APECED) had impaired DC maturation (212). Similar to our results, these DC 
showed enhanced production of TNF-α and IL-8 and reduced capacity to prime T cells (56, 
212).  
7.2 Farnesol regulation of CD1 molecules and its functional impact 
The most prominent effect observed after dendritic cells differentiation in presence of FOH 
was the displacement in the expression of CD1 molecules. While CD1a expression was not 
upregulated, CD1d was enhanced during DC differentiation in the presence of FOH (56). 
CD1 molecules present lipid antigens to different T cells subsets. In particular, CD1a are 
specialized in presenting lipid antigens to T cells, while CD1d present antigens to iNKT cells 
(85). iNKT cells are a subpopulation of T cells with the capacity to modulate immune 
responses due to its capability to produce high amounts of pro-inflammatory and anti-
inflammatory cytokines. Thereby, the shift in the CD1 molecules expression pattern may 
influence the outcome of infection, since iNKT cells are known to be important during 
infection against pathogenic microorganisms (213-215). However, there are discrepancies 
regarding the role of iNKT cells during C. albicans infection. Cohen et al. showed that iNKT 
cells activation reduces disease progression in a murine model of systemic candidiasis 
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(213). Similarly, iNKT cells recognize C. albicans α-manosyl residues in a CD1d-dependent 
manner and increases the survival of mice co-infected with S. pneumoniae (215). 
Nevertheless, different reports showed that iNKT cells have no role or that activation of these 
cells promotes susceptibility to systemic C. albicans infection due to high IL-10 production 
(216, 217). Thus, more research to elucidate the role of iNKT cells during C. albicans 
infection is needed. While a higher expression of CD1d correlates with an elevated capacity 
to activate iNKT cells, we failed to observe an enhanced expansion of these cells when co-
cultured with FOH-differentiated mDC (87, 156). One possibility could be that FOH-
differentiated DC have an impaired capacity to present antigens to T cells. Nakken et al. 
showed that endosomal processing of antigens by proteases is necessary for proper 
induction of iNKT expansion by DC (178). However, the antigen used in this study (α-
GalCer) does not require preprocessing and readily binds to CD1d complex (218). Thereby, 
a different mechanism should be involved in the reduced capacity of FOH-mDC to activate 
iNKT cells. In concert with signals triggered by CD1d-mediated lipid presentation, 
costimulatory molecule interactions between DC and T cells, such as CD40:CD40L and 
CD80/CD86:CD28, and the release of IL-12 by DC is required for optimal iNKT expansion 
(219, 220). Indeed, a reduction in CD40 and CD80 was observed in DC differentiated with 
FOH. However, our results indicate that the shift in the IL-12/IL-10 secretion ratio play an 
essential role in FOH-differentiated mDC capacity to induce iNKT expansion, since 
reconstitution of IL-12 and IL-10 to levels observed in absence of FOH significantly improves 
DC capability to expand iNKT cells.  
This work gives insights into the molecular mechanisms by which FOH modulates CD1d 
expression in DC. Our results showed that FOH regulates CD1d expression via activation 
of the PPARα/RARα signaling pathway. Szatmari et al. demonstrated that activation of 
PPARγ leads to upregulation of retinaldehyde dehydrogenases (RALDH, ALDH1) that 
catalyze the production of all-trans retinoic acid (ATRA) (156). ATRA serves as a ligand for 
RARα which increases CD1d expression in human DC (156). However, proper lipid antigen 
processing and loading to CD1d molecules requires activation of the lysosomal aspartyl 
protease cathepsin D CTSD (178). Concurrent with the higher CD1d surface exposure on 
FOH-differentiated DC, analysis of the transcriptional data identified increased gene 
expression of NR target genes, including ALDH1A1 and CTSD. Our results confirm previous 
observations that FOH activates NR, such as PPARγ (209, 221-223). Mechanistically, FOH 
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could interact directly or indirectly with NR (209, 224). Interestingly, our data suggest that 
FOH could regulate NR activities through activation of MAPK signaling pathway. Indeed, 
inhibition of p38 MAPK partially restored CD1d basal levels in FOH-differentiated mDC. NR 
activities can be modulated independently of the presence of ligands through activation of 
the AF-1 N-terminal region, which serves as target for post-translational modifications, 
including phosphorylation (127, 128, 130, 131). Moreover, p38 inhibition showed to 
diminished PPARγ transcriptional activities in different cell types (225, 226). Finally, we 
found that FOH-differentiated DC have a higher activation of p38 MAPK compared to mock-
treated DC. Altogether, these results indicate that FOH modulates CD1d surface expression 
via activation of the PPARγ/RARα signaling pathway in a process partially dependent on 
p38 MAPK.  
7.3 Farnesol alters cytokines release through several pathways 
The results presented in this study confirm that FOH modulates cytokines and chemokines 
release by mDC. While production of pro-inflammatory cytokines/chemokines (e.g. TNF-α, 
IL-8, MCP-1), and the anti-inflammatory cytokine IL-10 was enhanced in FOH-differentiated 
mDC, T cell activating cytokine and chemokine (e.g. IL-12 and RANTES) was reduced after 
LPS stimulation. We found that FOH modulates the release of cytokines through a complex 
activation of NR, MAPK and NF-κB signaling pathways. In particular, TNF-α production in 
FOH-differentiated mDC was blocked in the presence of inhibitors for JNK MAPK, NF-κB, 
RARα and LXRα. Accordingly, Szanto et al. showed that RARα activation by natural and 
synthetic ligands promotes the expression of genes such as CYP27A1, an enzyme involved 
in ligand production for LXRα (227). Activation of LXRα also activates NF-kB, which 
enhances the secretion of pro-inflammatory TNF-α (191). Interestingly, the elevated release 
of anti-inflammatory IL-10 observed in FOH-differentiated mDC might be a possible 
mechanism to suppress the inflammatory milieu observed in our experiments. Indeed, IL-10 
production was blocked when p38 MAPK and NF-κB inhibitors were present in the culture 
and correlated with the secretion of pro-inflammatory cytokines and chemokines observed 
in FOH-differentiated mDC. Moreover, analyses of p38 MAPK and NF-κB phosphorylation 
confirmed that FOH-instructed mDC have a higher activation of these pathways compared 
to mock-treated mDC. However, the diminished secretion of IL-12 and RANTES indicate 
that FOH-instructed mDC have a reduced T cell activation capacity. Although RANTES 
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production was partially dependent on PPARγ activation, our results suggest that FOH 
suppresses IL-12 release through a MAPK, NF-κB and NR independent mechanism. IL-12 
gene expression is regulated by MAPK/AP-1, NF-κB and IRF signaling pathways (228). 
Previous results showed that IL-12p70 release was reduced in IRF-1 deficient DC (228, 
229). Moreover, TLR4 activation leads to IRF-3 recruitment to the IL-12p35 promoter, which 
enhances IL-12p70 synthesis (230). Thus, it is possible that FOH impairs IL-12p70 
production in mDC by modulating IRF activation. Interestingly, other microbial QS molecules 
are known to affect IL-12 release. Homoserine lactone and the Pseudomona aeruginosa 
quinolone signal have been shown to decrease IL-12 production by murine DC (210). 
Moreover, another molecule produced by C. albicans, CA-SIIF, is known to reduce CD1a 
expression and IL-12 secretion in human DC (231). These results suggest that IL-12 
reduction might be a mechanism used by C. albicans to overcome immune responses 
orchestrated by DC. 
In summary, our results showed that FOH promotes inflammation, while reduces T cell 
inducing cytokines and chemokines, in a process dependent on several signaling pathways, 
including NR, MAPK and NF-κB.  
7.4 Farnesol-treated DC have a lower capacity to activate different T cell 
subsets 
DC are considered to be the bridge between the innate and adaptive branch of immunity, 
due to its potent capacity to present antigens and consequently activating T cell-specific 
responses (65). The altered expression of costimulatory molecules and cytokines release 
induced by FOH might indicate an impaired capacity of FOH-differentiated DC to activate T 
cells. Indeed, FOH-instructed mDC have a lower capability to activate Th1, iNKT and Treg 
cells. IFN-γ produced by Th1 lymphocytes is essential for stimulation of antifungal activity 
by neutrophils (97). The role of IFN-γ in anti-Candida immunity is highlighted by the 
enhanced mortality observed in IFN-γ-deficient mice infected with C. albicans and the 
elevated susceptibility of HIV-infected individuals with low CD4+ T cell count to develop 
oropharyngeal candidiasis (232, 233). Moreover, IFN-γ contributes to antifungal immunity 
by inducing nitric oxide production by macrophages, while reducing Candida-specific 
immunoglobulins (234). In agreement with our data, the bacteria QS molecule homoserine 
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lactone and P. aeruginosa quinolone signal has been shown to alter DC capacity to induce 
activation of T cells (210, 211). However, this is the first report that shows a negative effect 
of QS molecules in DC capacity to activate FOXP3+ Treg cells. While Th1 cells orchestrate 
antifungal immunity mainly by activating phagocytes, Treg are involved in controlling 
inflammation by suppressing the secretion of pro-inflammatory cytokines (235). Indeed, Treg 
expand during disseminated infection and produce high amounts of IL-4, TGF-β and IL-10, 
which blocks Th1 immunity (236, 237). Surprisingly, Treg could improve immunity against 
pathogenic fungi via an alternative mechanism. Treg was shown to promote Th17 
differentiation during systemic candidemia and oropharyngeal candidiasis (98, 236). IL-17 
play an important role in anti-fungal immunity and exerts its function mainly through 
recruitment and activation of neutrophils (98, 238). The reduced expression of costimulatory 
molecules observed in FOH-instructed mDC might influence the impaired capability of these 
cells to activate T cells. However, our results showed that surface molecules play a minor 
role in DC capability to induce Treg activation, since the enhanced expression of inhibitory 
receptors, such as ILT3 and PD-L1 did not correlate with increased FOXP3+ Treg expansion. 
Reconstitution of IL-12 and IL-10 release to normal levels was sufficient to restore the 
capacity of FOH-differentiated mDC to activate Th1 and Treg populations. IL-12 is an 
important cytokine involved in the differentiation and activation of T cells. IL-12 signals 
through the IL-12 receptor, triggers activation of the Janus kinase 2 (JAK2) and tyrosine 
kinase 2 (TYK2), leading to phosphorylation of family members of the STAT transcription 
factor, resulting in polarization of T cells into INF-γ producing Th1 cells (239). Interestingly, 
IL-12 signaling increased IFN-γ production in Treg while retaining FOXP3+ expression (240). 
Altogether, our results confirm that FOH acts as a compound with immune modulatory 
properties that blocks the capacity of DC to induce protective adaptive immunity. Since T 
cells play an important role during C. albicans infection, our results support the role of FOH 
as a virulence factor produce by this fungus to evade DC surveillance.  
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8 Conclusions 
Besides its well-known quorum sensing properties, FOH has been shown to be a modulator 
of immune function. FOH is able to activate monocytes, neutrophils and macrophages. 
Interestingly, this molecule altered DC differentiation and maturation while reducing their 
capacity to activate T cells. Due to the relevance of DC in orchestrating immune responses 
during infection, identification of the molecular mechanisms by which FOH regulates DC 
function could lead to possible targets for pharmacological strategies against C. albicans 
infection. Our findings showed for the first time that FOH modulates DC differentiation and 
maturation through activation of the nuclear receptors PPARγ, RARα and LXRα, MAPK and 
NF-κB signaling pathways (Figure 29). FOH activates the PPARγ/RARα axis to increase 
CD1d surface expression on DC in a process partially dependent on p38 MAPK signaling. 
We found that FOH increased the release of pro-inflammatory cytokines and anti-
inflammatory IL-10, and impaired IL-12 release mainly through the RARα, LXRα, MAPK and 
NF-κB signaling pathways. Despite multiple effects of FOH that in isolation suggest 
activation of DC, the net effect of FOH exposure is paralysis of DC function due to the 
reduced ability to prime several T cell subsets. In agreement, the altered secretion of IL-12 
and IL-10 induced by FOH treatment showed to play a key role in FOH-differentiated DC 
capacity to promote iNKT, Th1 and Treg cell activation. Due to the relevance of these cells 
in the anti-Candida immunity, besides its quorum sensing function, FOH can be viewed as 
a virulence factor enabling C. albicans to overcome the immune surveillance by DC.  
Further studies should focus in elucidating the molecular mechanisms underlying the 
diminished production of IL-12 in FOH-differentiated DC. One possibility might be to 
evaluate the IRF signaling pathway which is known to modulate IL-12 release in DC (228-
230). Furthermore, it would be interesting to characterize the interaction with Candida 
albicans in respect to phagocytosis and killing capacity. The current work shows evidences 
of the crosstalk between host nuclear receptors and molecules produced by C. albicans. 
Interestingly, fungi present nuclear-receptor like transcription factors (241, 242); thus, it 
would be interesting to elucidate the role of these transcription factors in the virulence of C. 
albicans and evaluate how molecules produced by host cells might interact with these 
transcription factors.  
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Figure 29. Farnesol modulates DC function through a coordinated activation of several 
signaling pathways 
FOH activates several intracellular signaling pathways resulting in a distinct DC subset, with altered 
expression of antigen-presenting and costimulatory molecules. FOH modulates the expression of 
CD1d via p38 MAPK-PPARγ/RARα signaling pathway. Moreover, FOH-differentiated DC showed an 
elevated secretion of pro-inflammatory and anti-inflammatory IL-10, through MAPK and NF-κB 
activation. Finally, FOH treatment reduces DC capacity to activate different T cell subsets, such as 
Th1, iNKT and Treg cells, via reduction of the IL-12/IL-10 secretion ratio.   
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10 List of abbreviations 
% Percent 
°C Degree Celsius 
Ab Antibody 
AGN RARα antagonist 
AP-1 Activator protein 1 
APC Allophycocyanin 
AM RARα agonist 
CD Cluster of differentiation 
CLR C-type lectin receptors 
DC Dendritic cells 
DMSO Dimethylsulfoxid 
DNA Deoxyribonucleic acid 
DPP3 Diacylglycerol pyrophosphate phosphatase 
e.g. exempli gratia 
EDTA Ethylenediaminetetraacetic acid 
ERK Extracellular-signal-regulated kinase 
et. al. et alii 
FBS Fetal bovine serum 
FCS Forward scatter 
FITC Fluorescein isothiocyanate 
FOH Farnesol 
FOXP3 Forkhead box P3 
g Acceleration due to gravity 
GM-CSF Granulocyte macrophage colony-stimulating factor 
GSK LXR antagonist 
GW PPARγ antagonist 
HLA-DR Human leukocyte antigen-D related 
iDC Immature dendritic cells 
IFN Interferon 
IL Interleukin 
ILT leukocyte Ig-like receptors 
iNKT Invariant Natural Killer T cells 
JNK c-Jun N-terminal kinase 
LXR Liver X receptor 
LPS Lipopolysaccharide 
MAPK Mitogen-activated protein kinase 
MCP Monocyte chemoattractant protein 
mDC Mature dendritic cells 
MHC Major histocompatibility complex 
mins Minutes 
MOH Methanol 
MOI Multiplicity of infection 
NFAT Nuclear factor activated T-cells 
NF-κB Nuclear factor kappa B 
NR Nuclear receptor 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate buffer saline 
PD-L Programmed death-ligand 
PE Phycoerythrin 
PerCP Peridinin chlorophyll 
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PMA Phorbol 12-merystate 13-acetate 
PPAR Peroxisome proliferator activated receptor 
PRR Pathogen recognition receptor 
QS Quorum sensing 
RANTES Regulated upon activation, normally T cell expressed and secreted 
RAR Retinoic acid receptor 
RXR Retinoic X receptor 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RPMI Roswell Park Memorial Institute medium 
RSG Rosiglitazone: PPARγ agonist 
STAT Signal transducer and activators of transcription 
SD  Standard deviation 
TGF-β transforming growth factor beta 
Th1 Type 1 helper T cell 
Th2 Type 2 helper T cell 
Th17 Type 17 helper T cell 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
Treg Regulatory T cells 
U Units 
V450 Violet 450 nm 
Vs Versus 
YPD Yeast peptone dextrose 
α Alpha 
β Beta 
γ Gamma 
µM Micromolar 
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